

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
A013

Total Pages in this Submission

## TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

Soluble Lymphotoxin-beta Receptors and Anti-Lymphotoxin Receptor and Ligand Antibodies As Therapeutic Agents for the Treatment of Immunological Diseases

and invented by:

BROWNING, Jeffrey; HOCHMAN, Paula Susan; RENNERT, Paul D. and MacKAY, Fabienne

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

Continuation    Divisional    Continuation-in-part (CIP)   of prior application No.: PCT/US 97/19436

Which is a:

Continuation    Divisional    Continuation-in-part (CIP)   of prior application No.: US 60/1029,060

Which is a:

Continuation    Divisional    Continuation-in-part (CIP)   of prior application No.: \_\_\_\_\_

Enclosed are:

### Application Elements

1.  Filing fee as calculated and transmitted as described below
  
2.  Specification having 70 pages and including the following:
  - a.  Descriptive Title of the Invention
  - b.  Cross References to Related Applications (*if applicable*)
  - c.  Statement Regarding Federally-sponsored Research/Development (*if applicable*)
  - d.  Reference to Microfiche Appendix (*if applicable*)
  - e.  Background of the Invention
  - f.  Brief Summary of the Invention
  - g.  Brief Description of the Drawings (*if drawings filed*)
  - h.  Detailed Description
  - i.  Claim(s) as Classified Below
  - j.  Abstract of the Disclosure

JC594 U.S. PT  
09/299139

04/23/99

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

A013

Total Pages in this Submission

## Application Elements (Continued)

3.  Drawing(s) (when necessary as prescribed by 35 USC 113)
  - a.  Formal Number of Sheets \_\_\_\_\_
  - b.  Informal Number of Sheets 8
4.  Oath or Declaration
  - a.  Newly executed (original or copy)  Unexecuted
  - b.  Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
  - c.  With Power of Attorney  Without Power of Attorney
  - d.  DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5.  Incorporation By Reference (usable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6.  Computer Program in Microfiche (Appendix)
7.  Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
  - a.  Paper Copy
  - b.  Computer Readable Copy (identical to computer copy)
  - c.  Statement Verifying Identical Paper and Computer Readable Copy

## Accompanying Application Parts

8.  Assignment Papers (cover sheet & document(s))
9.  37 CFR 3.73(B) Statement (when there is an assignee)
10.  English Translation Document (if applicable)
11.  Information Disclosure Statement/PTO-1449  Copies of IDS Citations
12.  Preliminary Amendment
13.  Acknowledgment postcard
14.  Certificate of Mailing  
 First Class  Express Mail (Specify Label No.): EM34049840US

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
A013

Total Pages in this Submission

**Accompanying Application Parts (Continued)**

15.  Certified Copy of Priority Document(s) (*if foreign priority is claimed*)

16.  Additional Enclosures (*please identify below*):

**Fee Calculation and Transmittal**

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
<b>Total Claims</b>	43	- 20 =	23	x \$22.00	\$506.00
<b>Indep. Claims</b>	7	- 3 =	4	x \$82.00	\$328.00
<b>Multiple Dependent Claims (check if applicable)</b>	<input type="checkbox"/>				\$0.00
				<b>BASIC FEE</b>	\$790.00
<b>OTHER FEE (specify purpose)</b>					\$0.00
				<b>TOTAL FILING FEE</b>	\$1,624.00

- A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2327 as described below. A duplicate copy of this sheet is enclosed.
- Charge the amount of \$1,624.00 as filing fee.
  - Credit any overpayment.
  - Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
  - Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Signature

Kerry A. Flynn, Esq.  
Reg. No. 33,693  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
(617) 679-3583

Dated:

4/23/99

CC:

## TECHNICAL FIELD OF THE INVENTION

This invention relates to compositions and methods comprising "lymphotoxin- $\beta$  receptor blocking agents" which 5 block lymphotoxin- $\alpha$  receptor signaling. Lymphotoxin- $\beta$  receptor blocking agents are useful for treating immunological diseases, more specifically for inhibiting antibody mediated immune responses, regulating the expression of addressins and cell trafficking, and influencing the differentiation of 10 follicular dendritic cells. This invention relates to soluble forms of the lymphotoxin- $\beta$  receptor extracellular domain, and antibodies directed against either the lymphotoxin- $\beta$  receptor or its ligand, surface lymphotoxin, that act as lymphotoxin- $\beta$  receptor blocking agents.

15

## BACKGROUND OF THE INVENTION

There are two arms of acquired immunity, which, while able to collaborate to achieve the common goal of eliminating antigen, are mediated by distinct participants of the immune 20 system with different effects. One arm of acquired immune response, humoral immunity, is mediated primarily by B cells and circulating antibodies. The other arm, referred to as cellular or cell-mediated immunity, is mediated by T cells that synthesize and elaborate cytokines which affect other 25 cells.

Activation and differentiation of B cells in response to most antigens requires that (1) B cells receive an antigen signal via their antigen specific receptor, membrane Ig, and (2) B cells receive contact dependent and independent signals 30 from activated T cells. The contact dependent costimulatory signal results from ligation of the CD40 receptor on B cells to the CD40 ligand expressed on activated T helper cells.

(Laman et al., Crit. Rev. Immunol., 16, pp. 59-108 (1996); Van

- Kooten and Banchereau, Adv. Immunol., 61, pp. 1-77 (1996)). Contact independent signaling is mediated by cytokines synthesized and elaborated by activated T cells. Together these contact dependent and independent signals drive B cells
- 5 to differentiate to either (1) memory B cells poised to mediate a more rapid response upon secondary exposure to antigen, or (2) antibody secreting plasma cells. Plasma cells, which are the terminal differentiation stage of B cells, synthesize and secrete antibodies.
- 10 T helper cells ("Th") play several significant roles in the immune system. Cytokines elaborated by Th cells at the onset of an immune challenge have been shown to affect which immune effector pathways are subsequently activated. Th cells are activated by the interaction of their antigen specific
- 15 receptor with antigen-presenting cells (APCs) displaying on their surfaces peptide fragments of processed foreign antigen in association with MHC class II molecules. Activated Th cells, in turn, secrete cytokines (lymphokines) which activate the appropriate immune effector mechanisms.
- 20 Th cells can be divided into three subgroups Th0, Th1 and Th2, based upon their cytokine secretion patterns. (Fitch et al., Ann. Rev. Immunol., 11, pp. 29-48 (1993)). In mice, non-stimulated "naive" T helper cells produce IL-2. Short term stimulation of Th cells leads to Th0 precursor cells,
- 25 which produce a wide range of cytokines including IFN- $\alpha$ , IL-2, IL-4, IL-5 and IL-10. Chronically-stimulated Th0 cells can differentiate into either Th1 or Th2 cell types, whereupon the cytokine expression pattern changes. Certain cytokines, for example IL-3, GM-CSF and TNF, are released by both Th1 and Th2
- 30 cells. Other cytokines are made exclusively by only one Th cell subgroup. (Romagnani et al., Ann. Rev. Immunol., 12 , pp. 227-57 (1994)). Th1 cells produce LT $\alpha$  IL-2 and IFN- $\gamma$  which activate macrophages and inflammatory responses associated

with cellular immunity and resistance to intracellular infections.

Th2 cells produce the cytokines IL-4, IL-5, IL-6 and IL-10 which increase eosinophil and mast cell production and 5 promote the full expansion and maturation of B cells. (Howard et al., "T cell-derived cytokines and their receptors", Fundamental Immunology, 3d ed., Raven Press, New York (1993)). Th2 cells also participate in generating B cell memory, somatic mutation and thus affinity maturation, and in 10 regulating de novo immunoglobulin isotype switching. For example, the Th2 cytokine IL-4 switches activated B cells to the IgG1 isotype while suppressing other isotypes. IL-4 also stimulates the overproduction of IgE in type I hypersensitivity reactions. The Th2 cytokine IL-5 induces the 15 IgA isotype important in mucosal immunity.

The secondary lymphoid tissues, such as the lymph nodes (LN), spleen and mucosal lymphoid tissues, are highly efficient in trapping and concentrating foreign substances, and are the main sites of antigen driven activation and 20 differentiation of T and B lymphocytes. These processes are dependent upon the diversity and organization of cells in these tissues, providing a framework for many aspects of humoral immune responses, such as T/B cell interactions, germinal center (GC) formation, affinity maturation, 25 immunoglobulin class switching and cell trafficking. (Klein, J., Immunology, John Wiley and sons, (1982)). The molecular mechanisms responsible for the development, structural maintenance and function of peripheral lymphoid tissues are not fully understood.

30 Although the general structure of the secondary lymphoid tissues differs markedly and shows variations between species of mammalia, the fine structure of these secondary lymphoid tissues shares certain features, such as, for example: (1) antigen accessibility, (2) structural features ensuring 35 continued contact of antigen with lymphocytes, (3) T cell rich

areas surrounded by B cells, (4) B cell rich follicles, (5) marginal zone type sites, (6) specialized endothelial cells, and (7) antibody production sites, as discussed in further detail below.

5       The secondary lymphoid tissues are accessible to antigen in the system. For example, antigen accesses the spleen via the sinusoidal blood supply, the LN via the afferent lymphatic vessels, and is transported across specialized epithelium into the mucosal lymphoid tissue.

10      The secondary lymphoid tissues in various species also share certain structural features such as follicular dendritic cells (FDC) and interdigitating cells (IDC), which ensure the continued presence of antigen in the lymphocyte rich areas of the tissues.

15      Another common feature is the presence of T cell rich areas surrounded by B cells. T cell rich areas include, for example, the periarteriolar lymphoid sheaths in the white pulp of the spleen, and the paracortical region of LN, which contain large numbers of recirculating T cells and IDC, which 20 in turn function as accessory cells for T and B cells.

25      Additionally, lymphoid tissues typically have B cell rich primary and secondary follicles in the white pulp of the spleen, and in the cortex of the LN. Secondary follicles in such lymphoid tissues are also called germinal centers (GC) and have a dense FDC network to capture and present antigens.

Marginal - zone type areas are also noted as defined histologic areas in the murine spleen and more diffuse sites in human secondary lymphoid organs. These areas are comprised primarily of marginal zone macrophages (MZM), metallophilic 30 macrophages (MM), marginal zone B cells and reticular cells, but may also include T cells and dendritic cells. (Kraal, Int. Rev. Cytol. 132, pp.31-74 (1992)). The opening of the arterial blood stream into the marginal zone areas gives antigens direct access to these cells and promotes cellular 35 reactions to antigens at this site. (Kraal, Int. Rev. Cytol.

132, pp.31-74 (1992)). The presence of MZM are also required for optimal trafficking of B cells in the splenic white pulp. (Kraal, 1992; Kraal, et al, Immunology, 68, pp.227-232(1989)).

Typically, blood lymphocytes enter the secondary lymphoid tissues by crossing specialized endothelium, for example the endothelial lining of the venules of LN (high endothelial venules -HEV) and the endothelial lining of splenic blood sinusoids in the marginal zone - like structures. This endothelium expresses adhesion molecules and addressins which function in the trafficking of cells to secondary lymphoid tissues. For example, peripheral LN addressins (PNAd) are distinct from the mucosal LN addressin, MAdCAM-1, which is involved in trafficking of lymphocytes to mucosal lymphoid tissues, including tissues such as the mesenteric LN, Peyer's patches and lamina propria.

Not all addressins are clearly defined, for example, the addressin for lymphocyte homing to spleen remains undefined. The physiological roles of these addressins include enhancing recruitment of appropriate sets of antigen specific lymphocytes into an immune response, and subsequent dissemination of the immune response throughout the body.

Finally, the plasma cells, which are the antibody producing plasma cells, are detected at different locations from where the progenitor B cells are activated by antigen. For example, antibody produced by plasma cells in splenic red pulp mainly results from B cell activation in T cell zones, and plasma cells in the medulla of LN are derived from B cells activated in T cell zones of the same node. Similarly, antibody produced by plasma cells in bone marrow are derivatives of B cells activated in spleen and lymph node, and plasma cells in the lamina propria of gut mainly derive from B cells activated in mesenteric LN or gut associated lymphoid tissue.

See e.g., ICM MacLennan, "The Structure and Function of Secondary Lymphoid Tissues" in Clinical Aspects of Immunology

5th edition, eds. P.J. Lachman, Sir D.K. Peters, F.S.Rosen, M.J.Walport, Blackwell Scientific Publications pp 13-30 (1993).

In general, the cellular/histologic events underlying a  
5 humoral immune response to T dependent antigens are as follows  
(Toellner, et al., J. Exp. Med., 183, pp. 2303-2312 (1996)):

In the *Inductive phase*, naive B and T cells are activated and recruited into the immune response in the days immediately after antigen enters the body. In the spleen, for example,  
10 within 12 hours of immunization for a secondary response, memory B cells encounter blood-borne antigen in the marginal zone and leave the marginal zone to go to the T cell zones. B cells can be detected in the T cell zones within 24 hours. Immunoglobulin switch transcripts can be detected within 12  
15 hours of secondary antigen exposure, thus indicating that the T-B cell interaction has already occurred. The B cells then migrate to the exit zones and red pulp where they proliferate to form foci of B cell blasts and differentiate into plasma cells. The B cells also continue to proliferate in the IDC rich T cell zone. Within 4 days after immunization, and after proliferation in the GC, B memory cell production will start.  
20 In a primary response, well developed GC are apparent by day 10 and reach peak size by day 14 post-immunization

T cell proliferation in the T cell zones becomes evident  
25 48-72 hours and peaks on day 7 after immunization. This T cell proliferation contributes to T cell dependent B cell activation. Proliferative levels in the T cell zone decrease as GC forms. T cell proliferation also occurs in the GC where centrocytes (B cells) in the dark zone pick up antigen from  
30 IDC, and present antigen to T cells in light zone.

T cell dependent antigen can activate marginal zone B cells, newly produced naive B cells and recirculating lymphocytes attracted to and retained in secondary lymphoid organs by addressins and adhesion molecules. Naive B cells

show the same kinetics for going to T cell zone, etc. as do the activated B cells.

Established Phase of T Cell Dependent Responses

5       The established phase of T cell dependent responses is maintained by the continued activation of memory B cells in the follicles of secondary lymphoid organs. There is very little recruiting of naive B cells at this stage, and the response is primarily driven by antigen retained on FDC. GC  
10      are required for optimal memory generation, isotype switching, somatic mutation and thus affinity maturation of immunoglobulin.

15      The mounting of such lymphocyte responses results in the production of antibodies able to circulate throughout the body by various routes, for example, antibodies leave the spleen via the blood, and exit LN via the efferent lymphatics. The antibodies thus encounter and directly bind to the invading pathogen. This recognition event sets off a cascade of immune effector mechanisms, including activation of the complement  
20      cascade and cellular reactions to mediate protection of the host from the pathogen.

25      Antibodies also play a role in some pathologic responses such as hypersensitivity responses - inappropriate or disproportionate immune responses evoked upon contact with a previously encountered antigen. There are four recognized types of hypersensitivity.

30      Type I "immediate hypersensitivity" involves allergen-induced Th2 cell activation and Th2 cytokine release. The Th2 cytokine IL-4 stimulates B cells to undergo isotype switching to produce IgE, which in turn activates mast cells to produce acute inflammatory reactions such as those which lead to eczema, asthma and rhinitis.

Types II and III hypersensitivity are caused by IgG and IgM antibodies directed against cell surface antigens or

specific tissue antigens (Type II) or soluble serum antigens to form circulating immune complexes (Type III).

Type IV "delayed type" hypersensitivity (DTH) is a Th1 cell mediated response and can be transferred between mice by 5 transferring Th1 cells, but not by transferring serum alone. This feature distinguishes Type IV DTH from the other three types of hypersensitivity, which require humoral immune responses caused primarily by antibodies which can be transferred in cell-free serum. (Roitt et al., Immunology, 10 pp. 19.1-22.12 (Mosby-Year Book Europe Ltd., 3d ed. 1993))

Pathological humoral immune responses are associated with a number of organ-specific and systemic autoimmune conditions such as Systemic Lupus Erythematosus, Wegener's Granulomatosis, Polyarteritis Nodosa (PAN), Rapidly 15 Progressive Crescentic Glomerulonephritis and Idiopathic Thrombocytopenia Purpura, as well as chronic inflammatory diseases such as the Graves' and Chagas' disease. Humoral immune responses may also contribute to grafted tissue and transplanted organ rejection.

20 The treatment of these various immunological conditions to date has generally employed immunomodulatory and immunosuppressive agents. Three general immunosuppressive agents currently used are steroids, cyclophosphamide and azathioprine.

25 Steroids are pleiotropic anti-inflammatory agents which suppress activated macrophages and inhibit the activity of antigen presenting cells in ways which reverse many pathologic T cell effects. Cyclophosphamide, an alkylating agent, mediates cell death by inhibiting DNA replication and repair. 30 Azathioprine is an anti-proliferative agent which inhibits DNA synthesis. These non-specific immunosuppressive agents are generally required in high doses which increase their toxicity (e.g. nephro- and hepatotoxicity) and cause adverse side effects. They are thus unsuitable for long term therapies.

Thus, there is an unmet need for additional agents and therapies which overcome the problems caused by conventional treatments.

## 5

SUMMARY OF THE INVENTION

The present invention solves the problems referred to above by providing pharmaceutical compositions and methods for treating immunological diseases by inhibiting lymphotoxin- $\beta$  receptor (LT- $\beta$ -R) signaling using lymphotoxin- $\beta$  receptor blocking agents. More particularly, the compositions and methods comprising LT- $\beta$ -R blocking agents are useful for inhibiting antibody mediated immune responses, for regulating addressin expression levels and cell trafficking, for influencing the differentiation of follicular dendritic cells, and for altering the structural organization of secondary lymphoid tissues and similar lymphoid structures arising in pathologic conditions such as, for example, systemic lupus erythematosus and idiopathic thrombocytopenia purpura. Additionally, in certain embodiments the claimed invention is useful for altering the association between immune complexes and B cells. More specifically, the methods of the invention can prevent the presentation or deposition of antigens on cells, or alternatively, to essentially dissolve or erase the antigens already present on cells.

In alternative embodiments, the LT- $\beta$ -R blocking agent is selected from the group consisting of soluble lymphotoxin- $\beta$ -R, an antibody directed against LT- $\beta$ -R, and an antibody directed against surface LT ligand.

In one embodiment, soluble forms of the lymphotoxin- $\beta$  receptor extracellular domain that act as LT- $\beta$ -R blocking agents are provided. The preferred compositions and methods of this embodiment comprise a recombinant lymphotoxin- $\beta$

receptor fusion protein that has the LT- $\beta$ -R extracellular ligand binding domain fused to an immunoglobulin constant heavy chain domain. More preferably, the LT- $\beta$ -R ligand binding domain is fused to a human IgG Fc domain.

5 In another embodiment of this invention, antibodies that act as LT- $\beta$ -R blocking agents are provided. Preferred compositions and methods of this embodiment comprise one or more antibodies directed against the lymphotoxin- $\beta$  receptor. More preferably, the antibody is a monoclonal antibody. Other  
10 preferred compositions and methods of this embodiment comprise one or more antibodies directed against surface lymphotoxin. More preferably, the antibody is a monoclonal antibody directed against lymphotoxin- $\beta$ . Preferred antibodies include the anti-human BT- $\beta$ -R mAb BDA8, and anti-human LT- $\beta$  mAb B9.

15 In yet other embodiments, the claimed invention relates to methods of altering the humoral immune response in an animal by administering a pharmaceutical composition which has a therapeutically effective amount of a LT- $\beta$ -R blocking agent. In certain other embodiments, the pharmaceutical  
20 composition is administered in an amount sufficient to coat LT- $\beta$ -R positive cells for about 1 to about 14 days. The pharmaceutical composition may in certain embodiments further comprise a pharmaceutically acceptable carrier or adjuvant.

In other embodiments, the claimed methods inhibit LT- $\beta$ -R  
25 signaling without inhibiting TNF-R signaling, using the LT- $\beta$ -R blocking agents described above. Methods of treating, preventing, or eliminating the human immunodeficiency virus in a mammal are also encompassed in the claimed invention, comprising administration of blocking agents of LT- $\beta$ -R either  
30 alone, or in conjunction with pharmaceutical carriers, adjuvants, or other drugs known to those skilled in the art to

be useful in the treatment or amelioration of the symptoms of HIV or AIDS.

Additionally, the present invention relates to methods of treatment in the transplantation field, i.e. graft rejection. Specifically, certain embodiments relate to the coadministration of a blocking agent of the CD40 pathway and a blocking agent of the LT pathway.

10           **BRIEF DESCRIPTION OF THE DRAWINGS**

**Figure 1** is a sequence of the extracellular portion of the human LT $\beta$  receptor which encodes the ligand binding domain.

15           **Figure 2** is an immunohistochemical analysis of the spleen of mice which received multiple injections of LT $\beta$ -R-Ig or LFA-3-Ig fusion proteins, and antigen.

20           **Figure 3** is an immunohistochemical analysis showing the absence of germinal centers from spleens of LT $\beta$ -R-Ig treated and MR-1 (anti-CD40 ligand antibody) treated mice, and the presence of follicular dendritic cells in spleens of MR-1 but not LT $\beta$ -R-Ig treated mice. Fusion proteins and SRBC antigen were administered as described for figure 2.

25           **Figure 4** is an immunohistochemical analysis showing addressin expression is altered in LN of mice treated in utero and continuously post-birth with LT $\beta$ -R-Ig.

30           **Figure 5** is an immunohistochemical analysis of Lymphocyte positioning and expression of macrophage markers in mesenteric LN of mice treated (as for figure 4) in utero and continuously post-birth with LT $\beta$ -R-Ig .

35           **Figure 6** is an immunohistochemical analysis showing that LT $\beta$ -R-Ig treatment of mice inhibits the antibody response to SRBC.

**Figure 7** is a representation of immune complex trapping on FDCs.

5

#### DETAILED DESCRIPTION OF THE INVENTION

In order that the invention herein described may be fully understood, the following detailed description is set forth.

The terms "immunoglobulin response" or "humoral response" as used herein refer to the immunological response of an animal to a foreign antigen whereby the animal produces antibodies to the foreign antigen. The Th2 class of T helper cells are important to the efficient production of high affinity antibodies.

The term "germinal center" as used herein refers to a secondary B cell follicle which forms after antigen immunization. The appearance of this histologic site correlates with optimal memory generation, isotype switching, somatic hypermutation and thus the affinity maturation of an antibody response.

The terms "marginal zone" or "marginal - zone type area" refer to histologically described compartments of the secondary lymphoid tissues comprised primarily of marginal zone macrophages (MZM), metallophilic macrophages (MM), marginal zone B cells and reticular cells, and also T cells and dendritic cells. The arterial blood stream opens into the marginal sinuses thus giving antigens direct access to these cells and promoting cellular reactions to antigens at this site.

The term "addressin" as used herein refers to a molecule involved in the homing of lymphocytes to secondary lymphoid organs. Such molecules are expressed on endothelial cells, specifically the high endothelial venules in the lymph nodes. The splenic addressin is undefined. MAdCAM-1 is a mucosal addressin; PNAd is a peripheral addressin.

The term "T helper (Th) cells" as used herein, refers to a functional subclass of T cells which help to generate cytotoxic T cells and which cooperate with B cells to stimulate antibody production. Helper T cells recognize 5 antigen in association with class II MHC molecules and provide contact dependent and contact independent (cytokine) signals to effector cells.

The term "cytokine", as used herein, refers to a molecule which mediates signaling between cells. A "lymphokine" is a 10 cytokine released by lymphocytes.

The term "Th2" refers to a subclass of T helper cells that produce LT $\alpha$ , interferon- $\gamma$  and IL-2 (and other cytokines) and which elicit inflammatory reactions associated with a cellular, i.e. non-immunoglobulin, response to a challenge.

15 The term "Th2" refers to a subclass of T helper cells that produces cytokines, such as IL-4, IL-5, IL-6 and IL-10, which are associated with an immunoglobulin (humoral) response to an immune challenge.

20 The term "Fc domain" of an antibody refers to a part of the molecule comprising the hinge, CH2 and CH3 domains, but lacking the antigen binding sites. The term is also meant to include the equivalent regions of an IgM or other antibody isotype.

25 The term "anti-LT $\beta$  receptor antibody" refers to any antibody that specifically binds to at least one epitope of the LT $\beta$  receptor.

The term "anti-LT antibody" refers to any antibody that specifically binds to at least one epitope of LT $\alpha$ , LT $\beta$  or a LT $\alpha/\beta$  complex.

30 The term "LT $\beta$ -R signaling" refers to molecular reactions associated with the LT $\beta$ -R pathway and subsequent molecular reactions which result therefrom.

The term "LT $\beta$ -R blocking agent" refers to an agent that can diminish ligand binding to LT $\beta$ -R, cell surface LT $\beta$ -R clustering or LT $\beta$ -R signaling, or that can influence how the LT $\beta$ -R signal is interpreted within the cell.

5 A LT $\beta$ -R blocking agent that acts at the step of ligand-receptor binding can inhibit LT ligand binding to the LT $\beta$ -R by at least 20%. Examples of LT $\beta$ -R blocking agents include soluble LT $\beta$ -R-Fc molecules, and anti-LT  $\alpha$ , anti-LT $\beta$ , anti-LT  $\alpha/\beta$  and anti-LT $\beta$ -R Abs. Preferably, the antibodies do not 10 cross-react with the secreted form of LT  $\alpha$ .

The term "LT $\beta$ -R biological activity" refers to: 1) the ability of the LT $\beta$ -R molecule or derivative to compete for soluble or surface LT ligand binding with soluble or surface LT $\beta$ -R molecules; or 2) native LT $\beta$  activity such as the ability 15 to stimulate an immune regulatory response or cytotoxic activity.

20 The term "LT ligand" refers to a LT  $\alpha/\beta$  heteromeric complex or derivative thereof that can specifically bind to the LT $\beta$  receptor.

25 The term "LT $\beta$ -R ligand binding domain" refers to the portion or portions of the LT $\beta$ -R that are involved in specific recognition of and interaction with a LT ligand.

30 The terms "surface LT" and "surface LT complex" refer to a complex comprising LT  $\alpha$  and membrane-bound LT $\beta$  subunits -- including mutant, altered and chimeric forms of one or more of the subunits -- which is displayed on the cell surface. "Surface LT ligand" refers to a surface LT complex or derivative thereof that can specifically bind to the LT $\beta$  receptor.

35 The term "subject" refers to an animal, or to one or more cells derived from an animal. Preferably, the animal is a mammal. Cells may be in any form, including but not limited

to cells retained in tissue, cell clusters, immortalized, transfected or transformed cells, and cells derived from an animal that has been physically or phenotypically altered.

5      **Lymphotoxin  $\beta$ : A Member of the TNF Family**

Tumor Necrosis Factor (TNF)-related cytokines have emerged as a large family of pleiotropic mediators of host defense and immune regulation. Members of this family exist in membrane-bound forms which act locally through cell-cell contact, or as secreted proteins which can act on distant targets. A parallel family of TNF-related receptors reacts with these cytokines and triggers a variety of pathways including cell death, cell proliferation, tissue differentiation and proinflammatory responses.

15      TNF, lymphotoxin  $\alpha$  (LT $\alpha$ , also called TNF $\beta$ ) and lymphotoxin  $\beta$  (LT $\beta$ ) are members of the TNF family of ligands, which also includes the ligands to the Fas, CD27, CD30, CD40, OX-40 and 4-1BB receptors. (Smith et al., Cell, 76, pp. 959-62 (1994)). Signaling by several members of the TNF family -- including  
20      TNF, LT $\alpha$ , LT $\beta$  and Fas -- can induce tumor cell death by necrosis or apoptosis (programmed cell death). In non-tumorigenic cells, TNF and many of the TNF family ligand-receptor interactions influence immune system development and responses to various immune challenges.

25      Most membrane-associated LT $\alpha/\beta$  complexes ("surface LT") have a LT $\alpha 1/\beta 2$  stoichiometry. (Browning et al., Cell, 72, pp. 847-56 (1993); Browning et al., J. Immunol., 154, pp. 33-46 (1995)). Surface LT ligands do not bind TNF-R with high affinity and do not activate TNF-R signaling. The LT $\beta$  receptor (LT $\beta$ -R), does however bind these surface lymphotoxin complexes with high affinity (Crowe et al., Science, 264, pp. 707-10 (1994)).

LT $\beta$ -R signaling, like TNF-R signaling, has anti-proliferative effects and can be cytotoxic to tumor cells. In

applicants' co-pending United States application serial number 08/378,968, compositions and methods for selectively stimulating LT $\beta$ -R using LT $\beta$ -R activating agents are disclosed. LT $\beta$ -R activating agents are useful for inhibiting tumor cell growth without co-activating TNF-R-induced proinflammatory or immunoregulatory pathways.

Recent gene targeting studies suggest a role for LT $\alpha/\beta$  in the development of secondary lymphoid organs. (Banks et al., J. Immunol., 155, pp. 1685-1693 (1995); De Togni et al., Science, 264, pp. 703-706 (1994)). Indeed, LT $\alpha$ -deficient mice lack lymph nodes (LN) and Peyer's patches (PP). Moreover, their spleens have disrupted architecture and the expression of functional markers on cells of the splenic marginal zone is altered. (Banks et al., 1995; De Togni et al., Science, 264, pp. 703-706 (1994); Matsumoto et al., Science, 271, pp. 1289-1291 (1996)). None of these characteristics have been described for either of the TNF receptor knock out mice. (Erickson et al., Nature, 372, pp.560-563 (1994); Pfeffer et al., Cell, 73, pp. 457-467 (1993); Rothe et al., Nature, 364, pp. 798-802 (1993). Applicants have recently defined a role for membrane LT $\alpha/\beta$  complexes in secondary lymphoid organ development by showing that the progeny of mice which had been injected during gestation with a soluble form of mouse LT $\beta$ -R fused to the human IgG1 Fc portion (LT $\beta$ -R-Ig) lacked most lymph nodes and showed disrupted splenic architecture. (Rennert et al, 1996, "Surface Lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs." J. Exp Med, 184: 1999-2006). In another study, mice transgenic for a similar LT $\beta$ -R-Ig construct which starts to be expressed three days after birth, were shown to have LN. However, their splenic architecture was disrupted and several markers of splenic marginal zone cells were not expressed

(Ettinger et al., "Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble LT $\beta$ -R/IgG1 fusion protein", Proc. Natl. Acad. Sci. U.S.A. 93: 13102-7). Together these data indicate there is a temporal requirement 5 for membrane LT functions to mediate effects on the development of secondary lymphoid organs, but not for effects on splenic architecture.

The TNF system may also function in development of the spleen. Splenic marginal zone cells of TNF-deficient mice do 10 not express macrophage markers or MAdCAM-1 (Alexopoulou et al., 60th Int. TNF Congress, Eur. Cytokine Network, pp. 228 (1996); Pasparakis et al., 60th Int. TNF Congress, Eur. Cytokine Network, pp. 239 (1996)). TNF-R55-deficient mice also lack MAdCAM-1 (but not MOMA-1) staining in the splenic 15 marginal zone. (Neumann et al., J. Exp. Med., 184, pp. 259-264 (1996), Matsumoto et al., Science, 271, pp. 1289-1291 (1996)). The expression of these markers as seen in the spleen of TNF-R75-deficient mice appears normal. (Matsumoto et al., Science, 271, pp. 1289-1291 (1996)).

20 Lymphoid-like tissues do not only arise as a part of developmental processes but also appear under some pathological circumstances such as chronic inflammation, a process recently termed neolymphoorganogenesis. (Picker and Butcher, Annu. Rev. Immunol., 10, pp. 561-591 (1992), Kratz, 25 et al., J. Exp. Med., 183, pp. 1461-1471 (1996)). Such processes are apparently influenced by TNF family members. Mice transgenic for the LT $\alpha$  gene driven by the rat insulin promoter (RIP-LT) developed LT-induced chronic inflammatory lesions with characteristics of organized lymphoid tissues. 30 (Kratz, et al., J. Exp. Med., 1183, pp. 1461-1471 (1996); Picarella et al., Proc. Natl. Acad. Sci., 89, pp. 10036-10040 (1992)).

The evaluation of LT function during a T cell - dependent immune response, using LT $\alpha$ -deficient mice, showed the

necessity of LT for GC formation, possibly for maintaining an organized follicular dendritic cell (FDCs) structure, and for humoral responses. (Banks et al., J. Immunol., 155, pp. 1685-1693 (1995); Matsumoto et al., Science, 271, pp. 1289-1291 (1996); Matsumoto et al., Nature, 382, pp. 462-466 (1996)). TNF-R55-deficient mice also lack FDCs, fail to develop GC and fail to develop an optimal antibody response to sheep red blood cells (SRBC). This suggests that TNF-R55 might be triggered by soluble LT or TNF signals for most of these responses (Le Hir et al., J. Exp. Med., 183, pp. 2367-2372 (1996), Alexopoulou et al., 60th Int. TNF Congress, Eur. Cytokine Network, pp. 228 (1996); Pasparakis et al., 60th Int. TNF Congress, Eur. Cytokine Network, pp. 239 (1996)). A functional role for the surface LT/LT $\beta$ -R pathway in the humoral immune responses has to date been undefined.

The LT $\beta$  receptor, a member of the TNF family of receptors, specifically binds to surface LT ligands. LT $\beta$ -R binds LT heteromeric complexes (predominantly LT $\alpha$ 1/82 and LT $\alpha$ 2/81) but does not bind TNF or LT $\alpha$  (Crowe et al., Science, 264, pp. 707-10 (1994)). LT $\beta$ -R mRNAs are found in the human spleen, thymus and in general organs with immune system involvement. Although studies on LT $\beta$ -R expression are in their early stages, LT $\beta$ -R expression patterns appear to be similar to those reported for TNF-R55 except that LT $\beta$ -R is lacking on peripheral blood T and B cells and T and B cell lines.

Cell surface lymphotoxin (LT) complexes have been characterized in CD4 $^{+}$  T cell hybridoma cells (II-23.D7) which express high levels of LT. (Browning et al., J. Immunol., 147, pp. 1230-37 (1991); Androlewicz et al., J. Biol. Chem., 267, pp. 2542-47 (1992), both of which are herein incorporated by reference). The expression and biological roles of LT $\beta$ -R, LT subunits and surface LT complexes have been reviewed by C.F. Ware et al. "The ligands and receptors of the lymphotoxin system", in Pathways for Cytolysis, Current Topics Microbiol.

Immunol., Springer-Verlag, pp. 175-218 (1995) specifically incorporated by reference herein.

LTA expression is induced and LTA secreted primarily by activated T and B lymphocytes and natural killer (NK) cells.

5 Among the T helper cells, LTA appears to be produced by Th1 but not Th2 cells. LTA has also been detected in melanocytes. Microglia and T cells in lesions of multiple sclerosis patients can also be stained with anti-LTA antisera (Selmaj et al., J. Clin. Invest., 87, pp. 949-954 (1991)).

10 Lymphotoxin  $\beta$  (also called p33) is expressed on the surface of human and mouse T lymphocytes, T cell lines, B cell lines and lymphokine-activated killer (LAK) cells. LT $\beta$  is the subject of applicants' co-pending international applications PCT/US91/04588, published January 9, 1992 as WO 92/00329; and 15 PCT/US93/11669, published June 23, 1994 as WO 94/13808, which are herein incorporated by reference.

20 Surface LT complexes are primarily expressed by activated T (helper, Th1, and killer cells) and B lymphocytes and natural killer (NK) cells as defined by FACS analysis or immunohistology using anti-LTA antibodies or soluble LT $\beta$ -R-Ig fusion proteins. In applicants copending US application serial no. 08/505,606, filed July 21, 1995, compositions and methods for using soluble LT $\beta$  receptors and anti-LT $\beta$  receptor and ligand specific antibodies as therapeutics for the treatment 25 of immunological diseases mediated by Th1 cells are disclosed. Surface LT has also been described on human cytotoxic T lymphocyte (CTL) clones, activated peripheral mononuclear lymphocytes (PML), IL-2- activated peripheral blood lymphocytes (LAK cells), pokeweed mitogen-activated or anti- 30 CD40- activated peripheral B lymphocytes (PBL) and various lymphoid tumors of T and B cell lineage. Engagement of alloantigen-bearing target cells specifically induces surface LT expression by CD8 $^{+}$  and CD4 $^{+}$  CTL clones.

Applicants have described herein several immunological functions for surface LT, and show the effects of LT $\alpha/\beta$  binding reagents on the generation and character of immunoglobulin responses, maintenance of the cellular organization of secondary lymphoid tissues including effects on the differentiation state of follicular dendritic cells and germinal center formation, and addressin expression levels which influence cell trafficking. Thus applicants define therapeutic applications for surface LT $\alpha/\beta$  and LT $\beta$  receptor binding agents.

Until the present invention, however, the impact of LT- $\beta$ -R signaling on humoral, or immunogenic, responses has not been fully understood. The inventors have, for the first time, discovered that blocking the LT pathway, either LT- $\beta$  or LT- $\beta$ -R can alter the humoral immune response in an animal. Thus, the claimed invention in a broad embodiment relates to methods of altering the humoral immune response in an animal comprising the steps of administering a pharmaceutical composition which comprises a therapeutically effective amount of a blocking agent of the LT pathway, specifically preferred, LT- $\beta$ -R blockers.

Any blocking agent can be used in the invention, and one skilled in the art can easily determine agents which block the LT- $\beta$ -R. For example, such blocking agents may include small molecule inhibitors of the receptor, soluble lymphotoxin- $\beta$ -Receptor, antibodies directed against the LT- $\beta$ -R, and antibodies directed against the surface LT ligand. In preferred embodiments, the blocking agents comprise a soluble LT- $\beta$ -R having a ligand binding domain that can selectively bind to a surface LT ligand, and, more preferably, where the soluble LT- $\beta$ -R comprises a human immunoglobulin FC domain.

In other embodiments, preferred blocking agents include monoclonal antibodies directed against the LT- $\beta$ -R, including, preferably, anti-human LT- $\beta$ -R mAb BDA8, and anti-human LT- $\beta$  mAb B9. More preferred antibodies include A1.D5.18 5 and A0.D12.10. and BB-F6. In certain instances, it may be desirable to use a monoclonal antibody directed against a murine surface LT ligand.

The long term presentation of antigen by FDCs is likely to be important in autoimmune diseases where the 10 continual activation of the immune system by endogenous or autoantigens perpetuates the disease. Immune complex trapping on FDC's is illustrated in Figure 7. The ability to remove these immune complexes from the FDC would serve to reduce the amount of immune activation and dampen the disease or even 15 stop disease progression. Those autoimmune diseases that involve aberrant antibody responses are obvious targets for LT pathway inhibitors although other more "classically" T cell mediated autoimmune diseases may have unrecognized humoral components, and therefore may also be beneficially impacted.

Likewise, in the transplantation field, graft 20 rejection, i.e., host vs. graft disease and graft vs. host disease, require the presentation of antigen to perpetuate. The mechanisms described here for manipulating FDC may also apply to those problems associated with the recognition of 25 non-self, i.e. transplantation.

Additionally, the continued presentation of antigen or maintenance of antigen memory may play a role in those 30 autoimmune diseases caused by molecular mimicry. For example, the immune reaction to the lyme disease infectious agent Borrelia burgdorferi leads to an arthritis-like disease presumably because some antigenic epitope on this bacterium resembles a normal joint component. Removal of the FDC-retained lyme bacterium antigen may ameliorate lyme disease

induced arthritis. Such therapy would also be relevant to other cases of mimicry associated with infectious agents.

Applicants have surprisingly found that the administration of blocking agents of LT- $\beta$ -R are capable of interfering with the presentation and/or deposition of antigens on follicular dendritic cells. Typically, B cells recognize antigen as immune complexes bound to the surface of follicular dendritic cells. Follicular dendritic cells may retain the antigens for an unspecified period of time.

Periodical contact with the antigen retained on the FDC thus may be related to the memory retention of B cells. Thus, the claimed methods encompass numerous disease states which are dependent upon the presentation of antigen on dendritic cells.

The administration of blocking agents of the invention can be done prior to introduction of antigen into an animal, in which case the blocking agents will prevent all or a portion of the deposition of the antigen on the follicular dendritic cells, thereby preventing, or diminishing, the expected immunogenic response. Alternatively, the blocking agents of the invention can be administered to an animal at a point after the follicular dendritic cells have antigen associated with them. Applicants claimed methods can disrupt this association, such that the expected immunogenic response would then be diminished or abolished. Thus, the therapeutic methods of the invention can involve the elimination in whole or in part of the immune complexes already trapped in B cell follicles, or, the prevention, in whole or in part, of the trapping of immune complexes on B cell follicles.

The ability to disrupt the association between these antigen presenting follicular dendritic cells and the immune complexes appears to be unique to the LT- $\beta$  pathway. For example, anti-CD40L (MR-1) is another member of the TNF family and is also expressed on follicular dendritic cells. Like LT- $\beta$ -R/Ig, MR-1 has been shown to prevent germinal cell

formation, however, does not affect the expression of FDC markers. Anti-CD40-L, unlike LT- $\beta$ -R, does not prevent immune complex trapping on follicular dendritic cells, nor is it able to eliminate immune complexes previously trapped on follicular dendritic cells. Additionally, applicants have shown that anti-CD40-L does not affect the survival/maintenance of previously generated memory B cells.

Although the precise basis for the differences between the impact of anti-CD-40L and LT- $\beta$ -R blocking agents is not known, it is hypothesized that CD40 may provide survival signals to B cells. However, the LT system is critical to maintain follicular dendritic cells in a fully differentiated and functional state, a condition which appears to be necessary for germinal center reaction and memory B cell generation and maintenance. Thus, blocking the CD40/CD40L pathway may prevent generation of memory B cells, but will not affect the already established memory B cell pool. Blocking the LT pathway, on the other hand, prevents not only the generation and maintenance of memory B cells, but also affects the maintenance of previously generated memory B cells.

A further application of inhibition of the LT pathway lies in the treatment of viruses that form reservoirs in the follicular dendritic cell (FDC) compartment. The HIV virus is a good example of such a case. Following viral infection, large amounts of infectious virus reside on FDC's in the B cell follicles of the secondary lymphoid organs. (Heathe et al., 1995, "Follicular dendritic cells and human immunodeficiency virus infectivity.", Nature 377: 740-4). Virus is presumed to be complexed with either complement or immunoglobulin and bound to either Fc receptors or complement receptors or both. Thus, the virus exploits the normal mechanism of the immune system to retain antigen memory for long periods. During the course of the disease, active infection of lymphocytes occurs primarily at these sites. It

RECORDED - CERTIFIED - INDEXED

has been calculated that during the asymptomatic phase of infection, the pool of virus in this compartment is more than 10 fold larger than that contained in T cells and monocytes. (Cavert et al., 1997, "Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection", Science 276:960-4). In current HIV treatment modalities, multiple anti-viral agents are combined to reduce the viral load and to avoid escape of resistant variants. A likely limitation of this therapy lies in non-compliance with the therapy and during such intervals, residual virus is free to mutate allowing the development of resistant variants and thus circumventing the therapy process. While the viral load in the FDC compartment is dramatically impacted during multiple drug therapy, the drugs themselves are largely directed at viral replication machinery, and not at the non-replicating virus on FDC surfaces. Therefore, the viral reservoir on FDCs can serve as a re-inoculum following cessation of drug therapy. Moreover, the FDCs can convert neutralized virus to an infectious form further underscoring the importance of these cells to HIV pathogenesis.

Since inhibition of the LT pathway can cause FDCs to release immune complexes from the cell surface, HIV in the form of an immune complex could also be released. It would be desirable to release all of the HIV load in this compartment immediately prior to commencement of multiple therapy type regimes as the released virus should either be processed and removed from the body or upon infection, it would be sensitive to the drug therapy. Such a combination could reduce the residual viral load to very low levels possibly effecting a cure. In this case, either LT $\beta$ -R/Ig or blocking antibodies to either the ligand or the receptor would be useful. A potential treatment protocol would involve initiating drug therapy, and then within several days, release any bound virus with one or several treatments with LT pathway inhibitors.

Once the viral load was reduced, further treatment with LT directed agents would not be required.

While HIV is a particularly well studied example, it is likely that other viruses reside or hide on FDC's in a quiescent state awaiting for some event such as an immunological disturbance which leads to large amounts of additional antigen load, and consequently the release of bound virus from FDCs and virus reemergence. Therefore, this invention relates to any means of Lt pathway inhibition to avoid the complications of FDC bound virus.

10 This discovery has significant implications for a number of diseases which rely on the presentation of antigen on dendritic cells, and response generated by memory B cells.

15 LT $\alpha$ 1/ $\beta$ 2 signaling effectively and serves as an example of a therapeutically useful anti-LT $\beta$  blocking monoclonal.

Additionally, an anti-human LT alpha directed monoclonal antibody entitled AOD12 was able to block LT $\alpha$ 1/ $\beta$ 2 signaling well yet in contrast to most anti-human LT alpha monoclonal antibodies, it was poorly effective against LT $\alpha$  alone. These 20 monoclonal antibodies were obtained following immunization of mice with soluble LT $\alpha$ 1/ $\beta$ 2 ligand leading to the discovery of monoclonal antibodies with unique specificity. Furthermore, we maintain that anti-LT $\alpha$  monoclonal antibodies with specificity directed preferentially against the LT $\alpha$ 1/ $\beta$ 2 complex will be found only following this form of immunization 25 and not via immunization with LT alpha alone and hence comprises a unique class of anti-LT $\alpha$  antibodies.

#### EXAMPLES

30

##### **Materials and Methods**

###### **Mice**

Timed pregnant Balb/c mice were purchased from Jackson Laboratory (Bar Harbor, ME), housed under conventional barrier protection, and handled in accordance with institutional guidelines. Receptor-Ig proteins or mAbs were injected into 5 the tail vein (iv) of pregnant mice. Progeny of these mice and 5 week old female Balb/c mice (purchased from Jackson Laboratory, Bar Harbor, ME) were injected with fusion proteins via the intraperitoneal (ip) route.

10 *Fusion Proteins and Antibodies*

Fusion proteins comprised of the extracellular domain of either murine LT $\beta$ -R, human TNF-R55 or human LFA-3 (which does not bind murine CD2) fused to the hinge, C<sub>2</sub> and C<sub>3</sub> domains of human IgG1 were prepared as described (Force et al., J. Immunol., 155, pp. 5280-5288 (1995); Miller et al., J. Exp. Med., 178, pp. 211-222 (1993)). Purified human IgG1 used as a control was purchased from Protos Immunoresearch (San Francisco, CA). MR1, anti-mouse CD40 ligand antibody, was purchased from Pharmingen (San Diego, CA).

20 Antibodies (MOMA-1, ED3) specific for markers expressed by mouse metallophilic macrophages (MM), (ED3 recognizes sialoadhesin), or specific for mouse reticular fibroblasts (ER-TR-7) were purchased from Serotec (Oxon, UK). Antibodies specific for mouse B220, CD4, and MadCAM-1 (MECA 367) were 25 purchased from Pharmingen (San Diego, CA). An antibody (ER-TR-9) specific for a marker expressed by mouse marginal zone macrophages was provided by Dr. Reina Mebius (Vrije Universiteit, Amsterdam). Antibodies (FDC-M1 and FDC-M2) specific for mouse follicular dendritic cell (FDC) have been 30 described previously (Maeda et al., J. Immunol., 148, pp. 2340 - 2347 (1992)). Anti-mouse CR1 antibody (which also stains FDC) was kindly supplied by Dr. Randolph J. Noelle (Dartmouth Medical School). Detection of peripheral lymph node addressin (PNAd) utilized the antibody MECA 79 (cell culture supernatant 35 derived from cells purchased from ATCC, Rockville, MD).

*Antigens and immunizations*

Mice were immunized ip with 100  $\mu$ l of a 10% suspension of SRBC (purchased from the Colorado Serum Company). This is 5 equivalent to 1 -  $5 \times 10^8$  SRBC per immunization.

*Immunohistochemistry*

Spleen and lymph nodes were frozen in OCT embedding medium (Miles, Elkhart, IN) and mounted for cryostat 10 sectioning. Sections 7-10 mm thick were dried and fixed with acetone. Sections were incubated with conjugated antibodies 15 for 1 hr at room temperature in a humidified box after dilution in Tris buffered saline buffer A (TBS-A, 0.05M Tris, 0.15M NaCl, 0.05% Tween-20 (v/v), 0.25% bovine serum albumin (BSA)), rinsed in TBS-B (0.05M Tris, 0.15M NaCl, 0.05% Tween-20) and fixed 1 min in methanol before initiating the enzymatic reaction. Horseradish peroxidase (HRP) and alkaline phosphatase (AP) activities were developed using the DAB tablet substrate kit (Sigma, St. Louis, MO) and 20 5-bromo-4-chloro-3-indolyl phosphate/ nitro blue tetrazolium (BCIP/NBT, Sigma), respectively. Tissue sections were fixed for 5 min in methanol and counter stained with Giemsa (Fluka, Buchs, Switzerland).

25 *Fluorescence Image Analysis*

For immunofluorescence staining, frozen sections were acetone fixed, air dried and preblocked with 5  $\mu$ g/ml anti-CD16/CD32 Fc block (Pharmingen, San Diego CA) in Tris Buffered Saline with 0.25% BSA, 0.05% Tween-20 and 10% heat aggregated 30 rabbit serum. Sections were stained in the same buffer using the following mAbs and detection reagents: 10  $\mu$ g/ml biotinylated anti-B220 mAb (Pharmingen) followed by 20  $\mu$ g/ml streptavidin-FITC (Southern Biotechnology Associates, Birmingham, AL); 10  $\mu$ g/ml of MECA 367 followed by 10  $\mu$ g/ml PE-35 goat F(ab')2 anti-rat IgG (Southern Biotechnology Associates);

culture supernatant of MECA79 followed by 20 µg/ml FITC-mouse anti-rat IgM (Pharmingen); 20 µg/ml anti-Sialoahesin mAb followed by 10 µg/ml PE-goat F(ab')2 anti-rat IgG (Southern Biotechnology Associates), 50 µg/ml biotinylated PNA (Vector Laboratories, Burlingame, CA) followed by 10 µg/ml streptavidin-PE (Southern Biotechnology Associates); 1:5 dilution of mAb MOMA-1 cell culture supernatant followed by 20 µg/ml FITC-mouse anti-rat IgM (Pharmingen). Some sections were stained with multiple mAbs simultaneously to allow image overlay analysis. All sections were viewed under 50X optics and photographed using Ektachrome P1600 (Kodak, Rochester, NY) or captured as separate red and green image files as described (Rennert et al, J. Exp. Med. (November 1996, in press)).

15 *Hemagglutination assays*

Serial dilutions of sera were made in 96 well microtiter plates (Costar, Cambridge, MA) in PBS/1% glucose. The SRBC-specific IgM titer was determined by adding 25 µl of a 10% SRBC suspension in each well and incubating the plate 1 hr in a humidified 37°C incubator. For SRBC-specific IgG, sera was incubated for 30 min at 37°C with 20 µl/well of 1% 2-mercaptoethanol (vol/vol) (Bio-Rad, Richmond, CA) to eliminate IgM pentamers. Then 25 µl/well of a 10% SRBC suspension was added, followed by 25 µl/well of a 10 mg/ml solution (in PBS/1% glucose) of goat anti-mouse IgG (Southern Biotechnology, Birmingham, AL) as a crosslinker agent for hemagglutination. The titer was determined as the reciprocal of last serum dilution for which hemagglutination is clearly apparent.

30

*ELISAs*

Analyses for receptor-Ig in plasma used mAbs specific for murine LT $\beta$ -R (Browning et al, manuscript in preparation), LFA-3 (Miller, et al., J. Exp. Med., 178, pp. 211-222 (1993)) or the CH3 domain of human IgG, (CDG5, prepared at Biogen)

directly immobilized (10 µg/ml) on 96 well microtiter plates for capture, and donkey anti-human IgG-Horse Radish Peroxidase (HRP) for detection (Jackson ImmunoResearch, West Grove PA , 1:4000 dilution).

5

#### **Production of Soluble LT $\beta$ -R Molecules**

The LT $\beta$ -R blocking agents in one embodiment of this invention comprise soluble LT $\beta$  receptor molecules. **Figure 1** shows the sequence of the extracellular portion of the human LT $\beta$ -R, which encodes the ligand binding domain. Using the sequence information in **Figure 1** and recombinant DNA techniques well known in the art, functional fragments encoding the LT $\beta$ -R ligand binding domain can be cloned into a vector and expressed in an appropriate host to produce a soluble LT $\beta$ -R molecule. Soluble LT $\beta$ -R molecules that can compete with native LT $\beta$  receptors for LT ligand binding according to the assays described in applicants copending US application serial no. 08/505,606, filed July 21, 1995, are selected as LT $\beta$ -R blocking agents.

A soluble LT $\beta$  receptor comprising amino acid sequences selected from those shown in **Figure 1** may be attached to one or more heterologous protein domains ("fusion domain") to increase the in vivo stability of the receptor fusion protein, or to modulate its biological activity or localization.

Preferably, stable plasma proteins -- which typically have a half-life greater than 20 hours in the circulation -- are used to construct the receptor fusion proteins. Such plasma proteins include but are not limited to: immunoglobulins, serum albumin, lipoproteins, apolipoproteins and transferrin. Sequences that can target the soluble LT $\beta$ -R molecule to a particular cell or tissue type may also be attached to the LT $\beta$ -R ligand binding domain to create a specifically-localized soluble LT $\beta$ -R fusion protein.

All or a functional portion of the LT $\beta$ -R extracellular region (**Figure 1**) comprising the LT $\beta$ -R ligand binding domain may be fused to an immunoglobulin constant region like the Fc domain of a human IgG1 heavy chain (Browning et al., *J. Immunol.*, 154, pp. 33-46 (1995)). Soluble receptor-IgG fusion proteins are preferable, and are common immunological reagents, and methods for their construction are known in the art (see e.g., United States Patent No. 5,225,538 incorporated herein by reference).

A functional LT $\beta$ -R ligand binding domain may be fused to an immunoglobulin (Ig) Fc domain derived from an immunoglobulin class or subclass other than IgG1. The Fc domains of antibodies belonging to different Ig classes or subclasses can activate diverse secondary effector functions. Activation occurs when the Fc domain is bound by a cognate Fc receptor. Secondary effector functions include the ability to activate the complement system, to cross the placenta, and to bind various microbial proteins. The properties of the different classes and subclasses of immunoglobulins are described in Roitt et al., *Immunology*, p. 4.8 (Mosby-Year Book Europe Ltd., 3d ed. 1993).

Activation of the complement system initiates cascades of enzymatic reactions that mediate inflammation. The products of the complement system have a variety of functions, including binding of bacteria, endocytosis, phagocytosis, cytotoxicity, free radical production and solubilization of immune complexes.

The complement enzyme cascade can be activated by the Fc domains of antigen-bound IgG1, IgG3 and IgM antibodies. The Fc domain of IgG2 appears to be less effective, and the Fc domains of IgG4, IgA, IgD and IgE are ineffective at activating complement. Thus one can select a Fc domain based on whether its associated secondary effector functions are

desirable for the particular immune response or disease being treated with the LT $\beta$ -R-Ig fusion protein.

If it would be advantageous to harm or kill the LT ligand-bearing target cell, one could select an especially active Fc domain (IgG1) to make the LT $\beta$ R-Ig fusion protein. Alternatively, if it would be desirable to target the LT $\beta$ R-Fc fusion to a cell without triggering the complement system, an inactive IgG4 Fc domain could be selected.

Mutations in Fc domains that reduce or eliminate binding to Fc receptors and complement activation have been described (S. Morrison, Annu. Rev. Immunol., 10, pp. 239-65 (1992)). These or other mutations can be used, alone or in combination, to optimize the activity of the Fc domain used to construct the LT $\beta$ -R-Ig fusion protein.

The production of a soluble human LT $\beta$ -R fusion protein comprising ligand binding sequences fused to a human immunoglobulin Fc domain (hLT $\beta$ -R-Ig) is described in Example 1. One CHO line made according to Example 1 that secretes hLT $\beta$ -R-Fc is called "hLT $\beta$ -R;hG1 CHO#14". A sample of this line was deposited on July 21, 1995 with the American Type Culture Collection (ATCC) (Rockville, MD) according to the provisions of the Budapest Treaty and was assigned the ATCC accession number CRL11965.

The production of a soluble murine LT $\beta$ -R fusion molecule (LT $\beta$ -R-Ig) is described in Example 2. A CHO line made according to Example 2 that secretes LT $\beta$ -R-Ig is called "mLT $\beta$ ;R-hG1 CHO#1.3.BB". A sample of this line was deposited on July 21, 1995 with the American Type Culture Collection (ATCC) (Rockville, MD) according to the provisions of the Budapest Treaty and was assigned the ATCC accession number CRL11964.

All restrictions on the availability to the public of the above ATCC deposits will be irrevocably removed upon the granting of a patent on this application.

Different amino acid residues forming the junction point of the receptor-Ig fusion protein may alter the structure, stability and ultimate biological activity of the soluble LT $\beta$  receptor fusion protein. One or more amino acids may be added to the C-terminus of the selected LT $\beta$ -R fragment to modify the junction point with the selected fusion domain.

The N-terminus of the LT $\beta$ -R fusion protein may also be varied by changing the position at which the selected LT $\beta$ -R DNA fragment is cleaved at its 5' end for insertion into the recombinant expression vector. The stability and activity of each LT $\beta$ -R fusion protein may be tested and optimized using routine experimentation and the assays for selecting LT $\beta$ -R blocking agents described herein.

Using the LT $\beta$ -R ligand binding domain sequences within the extracellular domain shown in **Figure 1**, amino acid sequence variants may also be constructed to modify the affinity of the soluble LT $\beta$  receptor or fusion protein for LT ligand. The soluble LT $\beta$ -R molecules of this invention can compete for surface LT ligand binding with endogenous cell surface LT $\beta$  receptors. It is envisioned that any soluble molecule comprising a LT $\beta$ -R ligand binding domain that can compete with cell surface LT $\beta$  receptors for LT ligand binding is a LT $\beta$ -R blocking agent that falls within the scope of the present invention.

#### **Source of Anti-LT $\beta$ -R Antibodies**

In another embodiment of this invention, antibodies directed against the human LT $\beta$  receptor (anti-LT $\beta$ -R Abs) function as LT $\beta$ -R blocking agents. The anti-LT $\beta$ -R Abs of this

invention can be polyclonal or monoclonal (mAbs) and can be modified to optimize their ability to block LT $\beta$ -R signalling, their in vivo bioavailability, stability, or other desired traits.

5 Polyclonal antibody sera directed against the human LT $\beta$  receptor are prepared using conventional techniques by injecting animals such as goats, rabbits, rats, hamsters or mice subcutaneously with a human LT $\beta$  receptor-Ig fusion protein (Example 1) in complete Freund's adjuvant, followed by  
10 booster intraperitoneal or subcutaneous injection in incomplete Freund's. Polyclonal antisera containing the desired antibodies directed against the LT $\beta$  receptor are screened by conventional immunological procedures.

15 Mouse monoclonal antibodies (mAbs) directed against a human LT $\beta$  receptor-Ig fusion protein are prepared as described in applicants copending US application serial no. 08/505,606, filed July 21, 1995. A hybridoma cell line (BD.A8.AB9) which produces the mouse anti-human LT $\beta$ -R mAb BDA8 was deposited on January 12, 1995 with the American Type Culture Collection  
20 (ATCC) (Rockville, MD) according to the provisions of the Budapest Treaty, and was assigned the ATCC accession number HB11798. All restrictions on the availability to the public of the above ATCC deposits will be irrevocably removed upon the granting of a patent on this application.

25 Various forms of anti-LT $\beta$ -R antibodies can also be made using standard recombinant DNA techniques (Winter and Milstein, Nature, 349, pp. 293-99 (1991)). For example, "chimeric" antibodies can be constructed in which the antigen binding domain from an animal antibody is linked to a human constant domain (e.g. Cabilly et al., US 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. U.S.A., 81, pp. 6851-55 (1984)). Chimeric antibodies reduce the observed immunogenic responses elicited by animal antibodies when used in human clinical treatments.

In addition, recombinant "humanized antibodies" which recognize the LT $\beta$ -R can be synthesized. Humanized antibodies are chimeras comprising mostly human IgG sequences into which the regions responsible for specific antigen-binding have been inserted (e.g. WO 94/04679). Animals are immunized with the desired antigen, the corresponding antibodies are isolated, and the portion of the variable region sequences responsible for specific antigen binding are removed. The animal-derived antigen binding regions are then cloned into the appropriate position of human antibody genes in which the antigen binding regions have been deleted. Humanized antibodies minimize the use of heterologous (inter-species) sequences in human antibodies, and are less likely to elicit immune responses in the treated subject.

Construction of different classes of recombinant anti-LT $\beta$ -R antibodies can also be accomplished by making chimeric or humanized antibodies comprising the anti-LT $\beta$ -R variable domains and human constant domains (CH1, CH2, CH3) isolated from different classes of immunoglobulins. For example, anti-LT $\beta$ -R IgM antibodies with increased antigen binding site valencies can be recombinantly produced by cloning the antigen binding site into vectors carrying the human  $\mu$  chain constant regions (Arulanandam et al., J. Exp. Med., 177, pp. 1439-50 (1993); Lane et al., Eur. J. Immunol., 22, pp. 2573-78 (1993); Traunecker et al., Nature, 339, pp. 68-70 (1989)).

In addition, standard recombinant DNA techniques can be used to alter the binding affinities of recombinant antibodies with their antigens by altering amino acid residues in the vicinity of the antigen binding sites. The antigen binding affinity of a humanized antibody can be increased by mutagenesis based on molecular modeling (Queen et al., Proc. Natl. Acad. Sci. U.S.A., 86, pp. 10029-33 (1989); WO 94/04679).

It may be desirable to increase or to decrease the affinity of anti-LT $\beta$ -R Abs for the LT $\beta$ -R depending on the targeted tissue type or the particular treatment schedule envisioned. For example, it may be advantageous to treat a patient with constant levels of anti-LT $\beta$ -R Abs with reduced ability to signal through the LT- $\beta$  pathway for semi-prophylactic treatments. Likewise, inhibitory anti-LT $\beta$ -R Abs with increased affinity for the LT $\beta$ -R may be advantageous for short-term treatments.

10

#### **Source of Anti-Surface LT Ligand Antibodies**

Another preferred embodiment of this invention involves compositions and methods which comprise antibodies directed against LT ligand that function as LT $\beta$ -R blocking agents. As described above for the anti-LT $\beta$ -R Abs, anti-LT ligand antibodies that function as LT $\beta$ -R blocking agents can be polyclonal or monoclonal, and can be modified according to routine procedures to modulate their antigen binding properties and their immunogenicity.

20

The anti-LT antibodies of this invention can be raised against either one of the two LT subunits individually, including soluble, mutant, altered and chimeric forms of the LT subunit. If LT subunits are used as the antigen, preferably they are LT $\beta$  subunits. If LT $\alpha$  subunits are used, it is preferred that the resulting anti-LT $\alpha$  antibodies bind to surface LT ligand and do not cross-react with secreted LT $\alpha$  or modulate TNF-R activity (according to the assays described in applicants copending US application serial no. 08/505,606, filed July 21, 1995).

25

Alternatively, antibodies directed against a homomeric (LT $\beta$ ) or a heteromeric (LT $\alpha/\beta$ ) complex comprising one or more LT subunits can be raised and screened for activity as LT $\beta$ -R

blocking agents. Preferably, LT $\alpha$ 1/ $\beta$ 2 complexes are used as the antigen. As discussed above, it is preferred that the resulting anti-LT $\alpha$ 1/ $\beta$ 2 antibodies bind to surface LT ligand without binding to secreted LT $\alpha$  and without affecting TNF-R activity.

The production of polyclonal anti-human LT $\alpha$  antibodies is described in applicants' co-pending application (WO 94/13808). Monoclonal anti-LT $\alpha$  and anti-LT $\beta$  antibodies have also been described (Browning et al., J. Immunol., 154, pp. 33-46 (1995)).

Mouse anti-human LT $\beta$  mAbs were prepared as described in applicants copending US application serial no. 08/505,606, filed July 21, 1995. A hybridoma cell line (B9.C9.1) which produces the mouse anti-human LT $\beta$ -R mAb B9 was deposited on July 21, 1995 with the American Type Culture Collection (ATCC) (Rockville, MD) according to the provisions of the Budapest Treaty, and was assigned the ATCC accession number HB11962.

Monoclonal hamster anti-mouse LT $\alpha$ / $\beta$  antibodies were prepared as described in applicants copending US application serial no. 08/505,606, filed July 21, 1995. A hybridoma cell line (BB.F6.1) which produces the hamster anti-mouse LT $\alpha$ / $\beta$  mAb BB.F6 was deposited on July 21, 1995 with the American Type Culture Collection (ATCC) (Rockville, MD) according to the provisions of the Budapest Treaty, and was assigned the ATCC accession number HB11963.

All restrictions on the availability to the public of the above ATCC deposits will be irrevocably removed upon the granting of a patent on this application.

30 **Use of soluble LT $\beta$ -R-Ig to inhibit the immunological functions of the surface LT complex.** We now show effects of a surface LT binding reagent, a fusion protein comprised of the extracellular domain of murine LT $\beta$ -R and the hinge, CH2 and

CH3 domains of human IgG1 (LT $\beta$ -R-Ig), on the generation and character of immunoglobulin responses, on the maintenance of the cellular organization of secondary lymphoid tissues including effects on the differentiation state of follicular 5 dendritic cells and germinal center formation, and on addressin expression levels which influence cell trafficking.

**10      Multiple injections of mice with LT $\beta$ -R-Ig alters the organization of splenic lymphocytes and the expression of functional markers by splenic marginal zone cells.**

The effect of surface LT blockade on the structure of the spleen was examined by giving mice six consecutive weekly injections of LT $\beta$ -R-Ig. Mice were then immunized with SRBC and given an additional injection of LT $\beta$ -R-Ig 4 days later. 15 Mice were sacrificed on day 10 after SRBC injection. Immunohistochemical staining of frozen spleen sections revealed several histologic changes. The follicles which comprise the splenic B cell compartment in normal mice are no longer discrete following LT $\beta$ -R-Ig treatment. Instead B cells 20 are now organized in a diffuse band surrounding the T cell areas (**Figure 2B**), and the boundary between the T and B cell zones is disrupted (**Figure 2B**). In contrast, in the control LFA-3-Ig treated mice the splenic B cell follicles are discrete and there is a clear demarcation between T and B cell 25 areas (**Figure 2A**).

Expression of cell surface markers recognized by the monoclonal antibodies ER-TR-9 and MOMA-1 is absent from two distinct macrophage populations residing in the splenic marginal zone of LT $\beta$ -R-Ig treated mice. ER-TR-9 is known to 30 stain a marker on MZM (Dijkstra et al., Immunol., 55, 23-30 (1985)) and MOMA-1 stains a marker on metallophilic macrophages (Kraal and Janse, Immunol., 58, 665-669, (1986)) (**Figure 2 D,F**, respectively). These markers are expressed on cells in control (LFA-3-Ig) treated mice (**Figure 2 C,E**).

Expression of sialoadhesin, another marker of MOMA-1+ macrophages in the murine splenic marginal zone, is also absent in LT $\beta$ -R-Ig treated mice (data not shown).

The antibody MECA-367 binds the adhesion molecule and mucosal addressin MAdCAM-1, originally described on endothelial cells in Peyer's patches, mesenteric lymph nodes, the intestinal mucosa and lamina propria (Briskin et al., *Nature*, 363, pp. 461-464 (1993); Nakache et al., *Nature*, 337, pp. 179-181 (1989)). MAdCAM-1 expression has also been described in the splenic marginal zone (presumably expressed on the endothelial cells of the small terminal arterioles opening onto the marginal sinus) and on the reticular meshwork within the germinal centers (Kraal et al., *Am. J. Pathol.*, 147, pp. 763-771 (1995)) (**Figure 2G**). MECA 367 staining of sections from LT $\beta$ -R-Ig treated mice show that MAdCAM-1 expression has been extinguished in the spleen (**Figure 2H**).

Likewise, the staining by the ER-TR-7 antibody (Van Vliet et al., *Cytochem.*, 34, pp. 883-890 (1986)) which delineates a population of reticular fibroblasts in the marginal zone (**Figure 2I**), is abnormally distributed and stronger in the white pulp of the LT $\beta$ -R-Ig than LFA-3-Ig treated animals (**Figure 2J**). The changes observed in LT $\beta$ -R-Ig treated mice were independent of antigen exposure as the pattern of staining was identical in LT $\beta$ -R-Ig treated unimmunized mice (data not shown).

***Germinat center formation is ablated and follicular dendritic cells are not detected in the spleens of LT $\beta$ -R-Ig treated mice.***

To determine at the histologic level whether multiple injections of mice of LT $\beta$ -R-Ig affects the immune response to SRBC, an analysis of germinal center (GC) formation and follicular dendritic cell (FDC) distribution in response to

antigen priming was performed. Frozen spleen sections from mice pretreated multiple times with LT $\beta$ -R-Ig or LFA-3-Ig as described for figure 2, were stained with peanut agglutinin (PNA) to delineate the GCs and with the FDC-M1 antibody to detect FDC, a cellular component required for GC formation (Schriever and Nadler, Adv. Immunol., 51, pp. 243-284 (1992); Tew et al., Immunol. Rev., 117, pp. 185-211 (1990)). The CD40-CD40 ligand interaction has also been shown to be critical for GC formation (Foy et al., J. Exp. Med., 180, pp. 157-163 (1994)). Thus for comparison, a group of mice was treated with MR1, an anti- mouse CD40 ligand antibody, following an injection protocol which has previously been shown to inhibit GC formation (Han et al., J. Immunol., 155, pp. 556-567 (1995)). Ten days after SRBC challenge, mice treated with the control LFA-3-Ig protein developed numerous PNA bright GC in the spleen (**Figure 3A**). GC were not detected in the spleen of LT $\beta$ -R-Ig or MR1-treated mice (**Figure 3 B,C** respectively). However, the effect of MR1 and LT $\beta$ -R-Ig can be distinguished by two additional observations. The staining for FDCs (FDC-M1) within the GC (**Figure 3D**) is absent in the spleen of LT $\beta$ -R-Ig treated mice (**Figure 3E**) but still present in the spleen of MR1-treated mice (**Figure 3F**). Similar observations was made using the FDC-M2 antibody to stain FDCs (data not shown). Thus LT $\beta$ -R-Ig treatment results in the phenotypic alteration of FDC in the spleen and the failure to form GC.

In addition to staining GC, PNA also stains the marginal zone in the spleen of normal mice. Such staining was also noted in LFA-3-Ig treated (**Figure 3A**) and MR1-treated mice (**Figure 3C**), but was absent in the spleen of LT $\beta$ -R-Ig treated mice (**Figure 3B**).

The expression of sialoadhesin, MOMA-1, ER-TR-9, ER-TR-7 and MAdCAM-1 in the spleen of MR1-treated mice was also shown

to be normal (data not shown), further distinguishing the molecular effects of interfering with CD40 and LT $\beta$ -R signaling.

5   *Kinetics of LT $\beta$ -R-Ig induced alterations of splenic lymphocyte organization and marginal zone cell markers expression*

The number of LT $\beta$ -R-Ig injections required to affect lymphocyte organization and expression of marginal zone cell markers in the spleen was analyzed. Mice were injected ip with LT $\beta$ -R-Ig either once or multiple times as indicated in Table 1. Some mice were then also immunized with SRBC on the day of the last LT $\beta$ -R-Ig injection. B220 and CD4 expression on B and T cells, respectively, and staining with PNA (for GC) and MECA367 (for MAdCAM-1), MOMA-1, ER-TR-9, and FDC-M1 was assessed on frozen spleen sections from treated mice. The kinetics of disappearance for the staining of metallophilic macrophages, marginal zone macrophages, MAdCAM-1, GCs and FDCs are shown to be distinct.

One injection of LT $\beta$ -R-Ig is sufficient to eliminate MAdCAM-1 staining a week later. Following three weekly LT $\beta$ -R-Ig injections, staining for GCs and FDCs is not detected and the T/B lymphocyte compartments are disrupted. A minimum of four LT $\beta$ -R-Ig injections are required to abolish the staining for metallophilic macrophages. Six LT $\beta$ -R-Ig injections do not completely ablate staining of marginal zone macrophages with ER-TR-9 antibody (also illustrated in Figure 2 D).

A more precise analysis of the rapid inhibition of MOMA-1, MAdCAM-1, FDC-M1, FDC-M2 and CR1 staining following a single injection of LT $\beta$ -R-Ig was done in the absence of antigen (Table 2).

Table 1: Effect of LTB<sub>β</sub>-R-Ig on splenic organization and germinal center formation in response to SRBC in adult mice.

Number of LTB <sub>β</sub> -R-Ig injections	T/B cell organization	Metallophilic macrophages *	Marginal zone macrophages *	MAcCAM-1 expression *	Germinal Centers §	FDC *
0	normal	+++	+++	+++	+++	+++
1	normal	++	+++	-	+	+
2	slightly abnormal	+	+++	-	+	+/-
3 †	disrupted	+	++	-	ND	ND
4 ‡	disrupted	+/-	++	-	ND	ND
5 ‡	disrupted	-	+	-	ND	ND
6	disrupted	-	+/-	-	-	-

Mice were injected ip with 100 µg of LTB<sub>β</sub>-R-Ig every week for 1 to 5 weeks and then sacrificed. LTB<sub>β</sub>-R-Ig was administered prior to SRBC ip injection (100 µl of a 10% suspension) unless otherwise indicated, and the last LTB<sub>β</sub>-R-Ig injection was given the same day as antigen. Animals were sacrificed 10 days after SRBC injection. Frozen spleen sections were double stained with biotinylated rat anti-mouse B220 and rat anti-mouse CD4, followed by streptavidin-alkaline phosphatase and mouse anti-rat IgG-peroxidase, respectively. Spleen sections were also stained with the following anti-mouse antibodies: rat anti-marginal zone macrophages (ER-TR9), rat anti-metallophilic macrophages (MOMA-1), rat anti-MAcCAM-1 (MECA 367) and rat anti-FDC (FDC-M1), followed by a mouse anti-rat IgG-peroxidase. An additional set of frozen sections was stained with biotinylated peanut agglutinin (PNA-biotin), followed by staining with streptavidin-peroxidase to detect germinal centers. Observations were made on sections from at least 3 animals per group.

\* The intensity of the staining was estimated by eye: normal staining: +++, reduced staining ++, weak staining +, and no staining -. The intensity of the staining on sections from non-treated animals and animals treated with LFA-3-Ig was taken as a reference for the normal staining.

§ The number of germinal centers per spleen section is recorded as follows: > 10; ++; 5-10; +; 1-5; +; none: -.

† Animals from these groups did not receive SRBC.

‡ ND: not done

Table 2: Precise timing of LT $\beta$ -R-Ig effects on the MOMA-1,  
MAdCAM-1, CR1, FDC-M1 and FDC-M2 staining

	DAYS AFTER A SINGLE INJECTION OF LT $\beta$ -R-Ig							
	0	1	3	5	7	10	14	
5	MOMA-1*	+++	+++	+++	+++	++	++	+
	MAdCAM-1*	+++	+/-	-	-	-	-	-
	CR1*	+++	+++	++	++	++	++	+
	FDC-M1*	+++	+/-	-	-	-	-	-
10	FDC-M2*	+++	+/-	-	-	-	-	-

Balb/c mice, 5-6 weeks received one ip injection of 100  $\mu$ g of LT $\beta$ -R-Ig or human Ig. Mice from each group were sacrificed on day 0, 1, 3, 5, 7, 10 and 14. Frozen spleen sections were stained with the following antibodies:

15 rat anti-mouse metallophilic macrophages (MOMA-1), rat anti-mouse MAdCAM-1 (MECA 367), rat anti-mouse FDC (FDC-M1), rat anti-mouse FDC (FDC-M2) and biotin-labeled rat anti-mouse CR1 followed by a mouse anti-rat Ig-peroxidase (MOMA-1, MAdCAM-1, FDC-M1 and FDC-M2) or peroxidase-labeled streptavidin (CR1).

20 \* The intensity of the staining was estimated by eye: normal staining: +++, reduced staining ++, weak staining +, and no staining -. The staining intensity on sections from untreated animals and animals treated with human Ig was taken as a reference for the normal staining. Sections from at least 2 animals per group were analyzed.

30 Balb/c mice which received a single ip injection of LT $\beta$ -R-Ig were sacrificed every day for fourteen days after injection and their spleens were removed and frozen. Frozen spleen sections were stained with MOMA-1, anti-MAdCAM-1 (MECA-367), and FDC specific reagents: FDC-M1, FDC-M2 and anti-CR1 antibodies. One day after LT $\beta$ -R-Ig injection, staining with anti-MAdCAM-1 FDC-M1 and FDC-M2 reagents was greatly reduced (Table 2). The faster inhibition of FDC-M1 staining in this experiment compared to results described in Table 1 may be due to the intensity of FDC-M1 staining which

is stronger in immunized animals. Staining for CR1 was still detectable at day 14 indicating that the FDC were still present on day 3 after treatment with LT $\beta$ -R-Ig but that the expression of markers detected with FDC-M1 and FDC-M2 was  
5 extinguished. Thus LT $\beta$ R-Ig treatment altered the FDC phenotype. Finally, MOMA-1 staining was reduced but still detected at day 14.

10 ***Multiple LT $\beta$ -R-Ig treatments inhibit addressin expression in LN.***

We examined addressin expression in LN of the progeny of timed pregnant Balb/c mice which were injected iv on days 14 and 17 of gestation with 200  $\mu$ g of receptor-Ig proteins. After birth the progeny were either untreated or injected once 15 per week with 100  $\mu$ g of LT $\beta$ -R-Ig, TNF-R55-Ig, or LFA-3-Ig ip. Fusion protein levels remained at or above 10  $\mu$ g/ml throughout life as determined by ELISA (data not shown). Immunohistochemical staining with MECA367 and MECA79 showed that MAdCAM-1 and peripheral LN addressins were entirely 20 absent in mesenteric LN from mice treated throughout life with LT $\beta$ -R-Ig (**Figure 4 A, B**). Sacral LN from these mice also lacked expression of all addressins and the cervical and iliac LN did not show peripheral lymph node (PNAd) staining (data not shown). The downregulation of addressin expression was 25 reversible, since expression recovered to normal levels in animals which were treated only in utero (**Figure 4 G, H**). In mice treated throughout life with 100  $\mu$ g/week TNF-R55-Ig or LFA-3-Ig, addressin expression in LN remained comparable to untreated mice (**Figure 4 C,D,E,F**).

30 ***B lymphocyte positioning and macrophage marker expression is altered in LN of LT $\beta$ -R-Ig treated mice.***

Antibodies which bind markers on macrophage populations in the LN subcapsular sinus (analogous to the splenic marginal

zone) were used to do immunohistochemical analysis of LN taken from mice which had been treated during gestation and continuously after birth as described for figure 4 above with LT $\beta$ -R-Ig, TNF-R55-Ig, or LFA-3-Ig. Fluorescent images were analyzed using image analysis software. Sialoadhesin expression is shown to be diminished in LN of mice treated with soluble LT $\beta$ -R-Ig (**Figure 5 B**), but not in LN of TNF-R55-Ig or LFA-3-Ig mice (**Figure 5 E, H**). MOMA-1 expression on macrophages in the subcapsular sinus was still detected in LN of mice treated with LT $\beta$ -R-Ig (**Figure 5 C**).

Effects of continuous LT $\beta$ -R-Ig treatment on lymphocyte organization in LN were also evaluated. LN sections were stained with mAbs specific for the B cell marker B220 and the T cell marker CD4. Image analysis was used in order to identify areas of overlap of T and B cell zones. Treatment with LT $\beta$ -R-Ig caused the dissolution of B cell follicles such that the B cells were present in a diffuse band on the outer margin of the T cell area (**Figure 5 A**). Despite the dissolution of their follicular structure, B cells were not present within T cell areas of the LN, instead they appeared in areas not normally occupied by lymphocytes. A very similar pattern of T and B cell staining was observed in mice treated throughout life with 100  $\mu$ g/week TNF-R55-Ig, but not LFA-3-Ig (**Figure 5 D**). Again B cell follicles were disrupted and B cells were present in areas of the LN not usually found to contain lymphocytes. Overlap of B cells with T cells was not observed.

***LT $\beta$ -R-Ig treatment of mice inhibits the IgM and IgG antibody response.***

The failure of splenic GC to form following SRBC priming of mice treated multiple times with LT $\beta$ -R-Ig (as in figure 3) suggested alterations in the humoral immune response of these

mice. To test this directly adult mice received six injections, once weekly, of LT $\beta$ -R-Ig or LFA-3-Ig and were then primed with SRBC. Mice were bled on days 7 and 14 postimmunization and the presence of SRBC-specific IgM and IgG in the sera was analyzed using hemagglutination assays. Seven days after SRBC immunization the IgM titer is normal but the IgG response is greatly diminished in LT $\beta$ -R-Ig treated mice as compared to mice treated with human Ig or PBS. (**Figure 6A**). On day 14 postimmunization, SRBC specific IgG still is not detected in the sera from LT $\beta$ -R-Ig treated mice and the titer of SRBC specific IgM in these mice is also decreased by more than half compared to human Ig or PBS treated mice (**Figure 6A**).

Ten days after SRBC priming GCs are detected in the spleens of mice treated once or twice with LT $\beta$ -R-Ig, however the number of GCs is greatly diminished compared to controls (Table 1). When mice received two injections of LT $\beta$ -R-Ig, the first injection a week before SRBC priming, and the second injection the same day as SRBC injection, the inhibition of the IgM and IgG response to SRBC at day 7 and day 14 (**Figure 6B**) is similar to that detected when mice received multiple LT $\beta$ -R-Ig injections (**Figure 6A**). At day 30 postimmunization, SRBC-specific IgG is not detected and the IgM levels are reduced by more than 80% compared to controls (**Figure 6 B**). Thus these LT $\beta$ -R-Ig treatment protocols resulted in the complete inhibition of IgG responses, and an abbreviated/diminished IgM response relative to the controls.

When mice received a single injection of LT $\beta$ -R-Ig on the same day as SRBC priming, the level of the IgG and IgM responses to SRBC on day 7 was comparable to that of the control groups (**Figure 6C**). However, on day 24 postimmunization the IgM and IgG titers are both reduced by 30%. At day 34 after SRBC priming, the titer of SRBC-specific

IgM is reduced by 50% compared to control groups and SRBC-specific IgG could not be detected (**Figure 6C**). These data show that this LT $\beta$ -R-Ig treatment protocol resulted in the marked abbreviation/reduction of the levels of both an ongoing IgM and IgG response, that is that LT $\beta$ -R-Ig treatment can inhibit a humoral response which has already been initiated.

#### **Antibody Mediated Diseases**

Many organ-specific and multisystem autoimmune conditions involve pathological antibody responses. Such conditions include: Myasthenia Gravis, autoimmune hemolytic anemia, Chagas' disease, Grave's disease, idiopathic thrombocytopenia purpura (ITP) Systemic Lupus Erythematosus (SLE), Wegener's Granulomatosis, Poly-arteritis Nodosa and Rapidly Progressive Crescentic Glomerulonephritis.  
(From Benjamini, et al. Immunology, A Short Course, (Wiley-Liss, New York 3d ed. (1996))

Although the etiology of SLE is undefined, a fair amount is known about the immunologic mechanism responsible for the pathology observed. For unknown reasons, patients with SLE produce antibodies against nuclear components of the body (antinuclear antibodies (ANA) notably against native double stranded DNA. Clinically the presence of these antibodies correlates best with the pathology of renal involvement in SLE. These antibodies complex with DNA apparently derived from the breakdown of normal tissue, and as in any immune - aggregate disease, such complexes form deposits trapped against the basement membrane of the glomeruli, in arteriolar walls and in joint synovial spaces. These complexes activate the complement cascade and attract granulocytes. The subsequent inflammatory reaction is characterized as glomerulonephritis, with resulting damage to the kidneys leading to proteinuria and hematuria.

Lupus nephritis has been studied in murine models for decades. Recently, the therapeutic efficacy of a reagent specific for the murine CD40 ligand was evaluated in such a model (Mohan, et al., J. Immunol., 154, pp. 1470-1480 (1995)).

5      The acceleration of lupus by the transfer of cells which induce the production of pathogenic antibodies *in vivo* was shown to be inhibited by administration of a monoclonal antibody which blocks CD40/CD40 ligand interactions. Moreover a brief treatment of lupus mice with anti-CD40 ligand antibody  
10     had a sustained beneficial effect on their spontaneous disease long after the antibody had been cleared from their systems. The experimentation indicated that pathogenic B cells could not produce antibody even 9 months after the therapy suggesting that there was a delay of the expansion of  
15     autoimmune memory B cells resulting in long-term therapeutic benefits. As we have shown that reagents which block LT $\alpha\beta$ /LT $\beta$ -R interactions *in vivo* inhibit the generation of antibody responses, alter the phenotype of FDC and the formation of germinal centers involved in optimal generation  
20     of B cell memory, the LT $\alpha\beta$ /LT $\beta$ -R blocking reagents of this invention will be useful for treating or preventing SLE.

The normal immune response to some pathogenic infectious agents also elicits autoantibody responses that can become excessive and present a medical problem. One example is  
25     Chagas' disease, an inflammatory cardiomyopathy which develops in humans and experimental animals with chronic Trypanosoma cruzi infection. Among the possible mechanisms involved in the pathogenesis of human Chagas' cardio-myopathy, induction of heart - specific autoimmune responses has recently received  
30     substantial experimental support. A recent study (Tibbetts, et al., J. Immunol., 152, pp. 1493 - 1499 (1994)) determined that cardiac antigen-specific antibodies are produced in T. cruzi - infected C57B1/6 mice with heart disease. Upon infection with the Brazil strain of T. cruzi, C57B1/6 mice

develop a cardiomyopathy that is histologically similar to that observed in chronically infected humans. Antisera from these mice react with three cardiac antigens while C57B1/6 mice infected with the Guayas strain of T Cruzi which do not 5 develop cardiomyopathy did not produce such antibodies. These data indicate that these antibodies are specific markers of cardiomyopathy. Thus the ability of LT $\beta$ -R blocking agents to inhibit damage mediated by autoantibodies can be assessed in such a rodent model.

10 Another example of cell destruction by autoantibodies generated as a consequence of certain infectious diseases or for other unknown reasons is idiopathic thrombocytopenia purpura (ITP). In this condition antibodies directed to platelets result in platelet destruction (by complement or 15 phagocytic cells with Fc or C3b receptor) which may lead to bleeding. Therapeutics which will inhibit such antibody mediated autoimmune reactions in vivo such as the LT- $\beta$ -R blocking agents of this invention -- which inhibit antibody generation -- will be useful to treat or prevent these 20 autoimmune diseases as well.

The normal immune response to some pathogenic infectious agents also elicits hypersensitivity reactions that can become excessive and present itself as a medical problem. The most prevalent example of type I hypersensitivity is allergic 25 reaction. These are mediated by IgE antibodies which bind via their Fc portion to receptors on mast cells and basophils to trigger the release of pharmacologically active agents that mediate anaphylaxis. ITP and Goodpasture's syndrome are sometimes thought to be Type II reactions which occur when IgM 30 or IgG antibodies bind to antigen on the cell surface and activate the complement cascade. Granulocytes are then attracted to the site of activation, and damage from the release of lytic enzymes from their granules results in the destruction of cells. Rheumatic arthritis is thought to

result from a type III hypersensitivity reaction mediated by immune complexes of antigen (in this case rheumatoid factor, an IgM autoantibody) that binds to the Fc portion of normal IgG. These immune complexes participate in causing  
5 inflammation of joints and the damage characteristic of this disease. As these pathologies are mediated in part by antibodies, therapeutics which will inhibit the generation of antibody such as the LT- $\beta$ -R blocking agents of this invention  
----- will be useful for treating or preventing these diseases  
10 as well.

#### **Treatments Using LT $\beta$ -R Blocking Agents**

The compositions of this invention will be administered at an effective dose to treat the particular clinical  
15 condition addressed. Determination of a preferred pharmaceutical formulation and a therapeutically efficient dose regimen for a given application is well within the skill of the art taking into consideration, for example, the condition and weight of the patient, the extent of desired  
20 treatment and the tolerance of the patient for the treatment.

Doses of about 1 mg/kg of a soluble LT $\beta$ -R are expected to be suitable starting points for optimizing treatment doses.

Determination of a therapeutically effective dose can also be assessed by performing in vitro experiments that  
25 measure the concentration of the LT $\beta$ -R blocking agent required to coat target cells (LT $\beta$ -R or LT ligand-positive cells depending on the blocking agent) for 1 to 14 days. The receptor-ligand binding assays described previously in applicants copending US application serial no. 08/505,606,  
30 filed July 21, 1995, can be used to monitor the cell coating reaction. LT $\beta$ -R or LT ligand-positive cells can be separated from activated lymphocyte populations using FACS. Based on the results of such in vitro binding assays, a range of

suitable LT $\beta$ -R blocking agent concentrations can be selected to test in animals.

Administration of the soluble LT $\beta$ -R molecules, anti-LT ligand and anti-LT $\beta$ -R Abs of this invention, alone or in combination, including isolated and purified forms of the antibodies or complexes, their salts or pharmaceutically acceptable derivatives thereof, may be accomplished using any of the conventionally accepted modes of administration of agents which exhibit immunosuppressive activity.

The pharmaceutical compositions used in these therapies may also be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms such as tablets, pills, powders, liquid solutions or suspensions, suppositories, and injectable and infusible solutions. The preferred form depends on the intended mode of administration and therapeutic application. Modes of administration may include oral, parenteral, subcutaneous, intravenous, intralesional or topical administration.

The soluble LT $\beta$ -R molecules, anti-LT ligand and anti-LT $\beta$ -R Abs of this invention may, for example, be placed into sterile, isotonic formulations with or without cofactors which stimulate uptake or stability. The formulation is preferably liquid, or may be lyophilized powder. For example, the soluble LT $\beta$ -R molecules, anti-LT ligand and anti-LT $\beta$ -R Abs of this invention may be diluted with a formulation buffer comprising 5.0 mg/ml citric acid monohydrate, 2.7 mg/ml trisodium citrate, 41 mg/ml mannitol, 1 mg/ml glycine and 1 mg/ml polysorbate 20. This solution can be lyophilized, stored under refrigeration and reconstituted prior to administration with sterile Water-For-Injection (USP).

The compositions also will preferably include conventional pharmaceutically acceptable carriers well known in the art (see for example Remington's Pharmaceutical Sciences, 16th Edition, 1980, Mac Publishing Company). Such

pharmaceutically acceptable carriers may include other medicinal agents, carriers, genetic carriers, adjuvants, excipients, etc., such as human serum albumin or plasma preparations. The compositions are preferably in the form of 5 a unit dose and will usually be administered one or more times a day.

The pharmaceutical compositions of this invention may also be administered using microspheres, liposomes, other microparticulate delivery systems or sustained release 10 formulations placed in, near, or otherwise in communication with affected tissues or the bloodstream. Suitable examples of sustained release carriers include semipermeable polymer matrices in the form of shaped articles such as suppositories or microcapsules. Implantable or microcapsular sustained 15 release matrices include polylactides (U.S. Patent No. 3,773,319; EP 58,481), copolymers of L-glutamic acid and ethyl-L-glutamate (Sidman et al., Biopolymers, 22, pp. 547-56 (1985)); poly(2-hydroxyethyl-methacrylate) or ethylene vinyl acetate (Langer et al., J. Biomed. Mater. Res., 15, pp. 167- 20 277 (1981); Langer, Chem. Tech., 12, pp. 98-105 (1982)).

Liposomes containing soluble LT $\beta$ -R molecules, anti-LT ligand and anti-LT $\beta$ -R Abs of this invention, alone or in combination, can be prepared by well-known methods (See, e.g. DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. U.S.A., 25 82, pp. 3688-92 (1985); Hwang et al., Proc. Natl. Acad. Sci. U.S.A., 77, pp. 4030-34 (1980); U.S. Patent Nos. 4,485,045 and 4,544,545). Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol.% cholesterol. The proportion of 30 cholesterol is selected to control the optimal rate of soluble LT $\beta$ -R molecule, anti-LT ligand and anti-LT $\beta$ -R Ab release.

The soluble LT $\beta$ -R molecules, anti-LT ligand and anti-LT $\beta$ -R Abs of this invention may also be attached to liposomes containing other LT $\beta$ -R blocking agents, immunosuppressive

agents or cytokines to modulate the LT $\beta$ -R blocking activity. Attachment of LT $\beta$ -R molecules, anti-LT ligand and anti-LT $\beta$ -R Abs to liposomes may be accomplished by any known cross-linking agent such as heterobifunctional cross-linking agents 5 that have been widely used to couple toxins or chemotherapeutic agents to antibodies for targeted delivery. Conjugation to liposomes can also be accomplished using the carbohydrate-directed cross-linking reagent 4-(4-maleimidophenyl) butyric acid hydrazide (MPBH) (Duzgunes et 10 al., J. Cell. Biochem. Abst. Suppl. 16E 77 (1992)).

**Advantages of therapeutic compositions comprising LT $\beta$ -R blocking agents**

The LT $\beta$ -R blocking agents of this invention are capable 15 of selectively inhibiting immune effector mechanisms. The inhibition of antibody mediated immunity is inhibited by multiple mechanisms including the regulation of GC formation by influencing FDC function. Both antibody and cell mediated immunity are inhibited in part by regulating the expression of 20 addressins and thus influencing lymphocyte trafficking. Thus LT $\beta$ -R blocking agents will be useful in treating conditions that are exacerbated by the activities of antibodies, or aberrant expression of addressins. The ability to selectively inhibit such immune mediated responses will be useful for 25 treating abnormalities including various autoimmune and chronic inflammatory conditions. As discussed above, treatment of such pathologic immune mediated conditions generally employs immunomodulatory and immunosuppressive agents which have pleiotropic effects on a wide variety of 30 cell types and immunological responses. These non-specific immunosuppressive agents are generally required in high and often cytotoxic doses that cause adverse side effects.

The ability of a reagent which inhibits antibody responses to ameliorate a pathologic immunological response is

supported in the recent study of mouse lupus nephritis. In the latter study, administration of an antibody that blocks the CD40/CD40L pathway was shown inhibit the acceleration of lupus nephritis produced upon transfer of cells which induce the  
5 production of pathogenic antibodies *in vivo*, and have a sustained beneficial effect on spontaneous disease long after the antibody had been cleared from the system. These data indicate that the LT $\beta$ -R blocking agents of this invention will be useful in suppressing cellular rejection of tissue grafts  
10 and organ transplants by inhibiting processes leading to the generation of antibody responses.

The LT $\beta$ -R blocking agents of the compositions and methods of this invention can be modified to obtain a desirable level of LT $\beta$ -R signalling depending on the condition, disorder or  
15 disease being treated. It is envisioned that the absolute level of LT $\beta$ -R signalling can be fine-tuned by manipulating the concentration and the affinities of the LT $\beta$ -R blocking agents for their respective molecular targets.

For example, in one embodiment of this invention,  
20 compositions comprising soluble LT $\beta$ -R molecules are administered to a subject. The soluble LT $\beta$  receptor can effectively compete with cell surface LT $\beta$  receptors for binding surface LT ligands. The ability to compete with surface LT ligands depends on the relative concentrations of  
25 the soluble and the cell surface LT $\beta$ -R molecules, and on their relative affinities for ligand binding.

Soluble LT $\beta$ -R molecules harboring mutations that increase or decrease the binding affinity of that mutant soluble LT $\beta$ -R with surface LT ligand can be made using standard recombinant  
30 DNA techniques well known to those of skill in the art. Large numbers of molecules with site-directed or random mutations can be tested for their ability to act as LT $\beta$ -R blocking

agents using routine experimentation and the techniques described herein.

Similarly, in another embodiment of this invention, antibodies directed against either the LT $\beta$  receptor or one or 5 more of the LT ligand subunits function as LT $\beta$ -R blocking agents. The ability for these antibodies to block LT $\beta$  receptor signalling can be modified by mutation, chemical modification or by other methods that can vary the effective concentration or activity of the antibody delivered to the 10 subject.

The ability to diminish LT $\beta$ -R signalling without completely inhibiting it may be important for establishing or maintaining reduced levels of LT $\beta$ -R signalling that support normal immune function while inhibiting antibody or cell 15 mediated responses which are exaggerated or abnormal.

Disruption of the LT $\alpha$  gene in a mouse leads to aberrant peripheral lymphoid organ development (De Togni et al., Science, 264, pp. 703-707 (1994)). Such mice lacked lymph nodes and their spleens lacked the usually clear demarcation 20 between T and B cell-rich regions in the follicles. We believe that this phenotype is associated with loss of surface LT-induced LT $\beta$ -R signalling because similar phenotypes have not been observed by modulating TNF-R activity. The ability to selectively or to partially block the LT $\beta$ -R pathway may thus 25 be useful in treating abnormal development of lymphoid-like structures resulting from chronic inflammation associated with mis- or over-expression of signalling by the LT $\beta$ -R pathway.

Antibodies are critical mediators of immune responses to pathologic agents. Thus the absolute inhibition of antibody 30 responses may not be desirable in certain circumstances. For example, antibodies are required to mediate resistance to infections by extracellular bacteria such as pneumococci and hemophilus.

The ability to influence the level of antibody generated by blocking LT $\beta$ -R signalling may be important in maximizing the beneficial results which can be achieved by treatments with the LT $\beta$ -R blocking agents of this invention.

5       The therapeutic methods of the invention involve selectively inhibiting responses that are dependent in whole or in part on the LT- $\beta$  pathway. The particular therapeutic uses of the claimed invention depend upon the relevant etiological mechanism of either the process to be inhibited, 10 or the medically desirable process to be promoted, as will be apparent to those of skill in the art. Thus, the methods of the invention involve, in various embodiments, administering a therapeutically effective amount of a blocking agent of the LT- $\beta$ -R, or LT- $\beta$ . The protein used in these methods may be 15 either full length proteins, fragments of the protein, or fusion fragments. In other embodiments, the methods involve the administration of a soluble fragment, such as a soluble lymphotoxin- $\beta$  receptor. In other preferred embodiments, the claimed invention relates to the administration of antibodies 20 against the LT- $\beta$ -R or LT- $\beta$ . The blocking agents of the invention may be administered concurrently with a therapeutically effective amount of a second compound which exerts a medically desirable effect.

For example, in certain methods for the treatment of AIDS 25 and/or HIV, one may desire to co-administer additional antiviral agents known in the art. For example, AZT, or protease inhibitors. Particularly preferred may be the administration of blocking agents of the invention, more preferably, LT- $\beta$ -R/IgG fusion protein, in combination with 30 AIDS "cocktail" therapy. These drug "cocktails" involve the administration to a patient of multiple drugs to reduce the amount of virus in the patient's systems.

Compositions of the invention may be formulated according to standard practice, such as prepared in a carrier vehicle. The term pharmaceutically acceptable carrier refers to one or more organic or inorganic ingredients, natural or synthetic, which 5 may facilitate the administration of the blocking agents of the invention to a patient. Suitable carriers are known to those of ordinary skill in the art.

Any of the compositions of the invention may be administered in any manner which is medically acceptable. 10 This may include injections, by parenteral routes, such as intravenous, intravascular, intraarterial, subcutaneous, intramuscular, intratumor, intraperitoneal, intraentriculare, intraepidural, or others, as well as oral, nasal, ophthalmic, rectal or topical. Sustained release administration is also 15 specifically included in the invention, b means such as depot injections or implants. Localized delivery may also be desirable. Modes of administration are easily defined by those skilled in the art.

The blocking agents of the LT pathway which are useful in 20 the claimed invention are intended to include functional derivatives of the soluble LT- $\beta$ -R, antibodies claimed herein. Functional derivatives include fragments, variants, analogs or chemical derivatives of a molecule. A fragment of a molecule, such as any of the antigens of the present invention is meant 25 to refer to any polypeptide subset of the molecule. A variant of such molecule is meant to refer to a naturally occurring molecule substantially similar to either the entire molecule, or a fragment thereof. An analog of the molecule refers to a non-natural molecule substantially similar to either the 30 entire molecule or a fragment thereof.

Variants of the blocking agents of the invention differ from naturally occurring agents in amino acid sequence, or in ways that do not involve sequence, or both. Variants in amino acid sequence are produced when one or more amino acids in the

naturally occurring molecules is substituted with a different natural amino acid, an amino acid derivative, or a non-native amino acid. Particularly preferred variants include the naturally occurring proteins, or biologically active fragments 5 of the naturally occurring proteins, whose sequences differ from the wild type sequence by one or more conservative amino acid substitutions. Such substitutions are well known by those skilled in the art, and typically have a minimal influence on the secondary structure and hydrophobic nature of 10 the blocking agent.

In other embodiments, variants with amino acid substitutions which are less conservative may also result in desired derivatives, e.g., by causing changes in charge, conformation and other biological properties. Such 15 substitutions would include for example, substitution of hydrophilic residues for a hydrophobic residues, substitution of a cysteine or a proline for another residue, substitution of a residue having a small side chain for a residue having a bulky side chain, or substitution of a residue having a net 20 positive charge for a residue having a net negative charge. When the result of a given substitution cannot be predicted with certainty, the derivatives may be readily assayed according to the methods disclosed herein to determine the presence or absence of the desired characteristics.

25 Variants within the scope of the invention include proteins and peptides with amino acid sequences having at least eighty percent homology with the blocking agents of the invention. More preferably the sequence homology is at least ninety percent, or at least ninety-five percent. For the 30 purposes of determining homology the length of comparison sequences will generally be at least 8 amino acid residues, usually at least 20 amino acid residues. Variants within the scope of the invention also include any blocking agent which 1) has an amino acid sequence which is at least forty percent 35 homologous to the sequence of the blocking agent, and also

which, 2) after being placed in an optimal alignment with the sequence of the blocking agent of the invention, has at least 80 % of its cysteine residues aligned with the cysteins of the blocking agent of the invention.

- 5       Also within the invention are agents which specifically bind to the blocking agents of the invention, including ligands and antibodies.

The following are examples which illustrate the soluble  
10      LT $\beta$  receptors, anti-LT ligand and anti-LT $\beta$ -R antibodies of this invention and the methods used to characterize them. These examples should not be construed as limiting: the examples are included for purposes of illustration and the present invention is limited only by the claims.

15

#### EXAMPLE 1

##### **Preparation of Soluble Human LT $\beta$ Receptors as Immunoglobulin Fc Fusion Proteins**

20      The sequence of a human cDNA clone isolated from a library of human 12p transcribed sequences derived from a somatic cell hybrid (Baens et al., *Genomics*, 16, pp. 214-18 (1993)), was entered into GenBank and was later identified as the sequence which encodes human LT $\beta$ -R. The sequence of this  
25      full-length human LT $\beta$ -R cDNA clone has been available since 1992 as GenBank entry L04270.

The extracellular domain of LT $\beta$ -R up to the transmembrane region (**Figure 1**) was amplified by PCR from a cDNA clone using primers that incorporated NotI and SalI restriction enzyme sites on the 5' and 3' ends, respectively (Browning et al., *J. Immunol.*, 154, pp. 33-46 (1995)). The amplified product was cut with NotI and SalI, purified and ligated into a NotI-linearized vector pMDR901 along with a SalI-NotI fragment encoding the Fc region of human IgG1. The resultant vector

contained the dihydrofolate reductase gene and the LT $\beta$ R-Ig fusion protein driven by separate promoters.

The vector was electroporated into CHO dhfr<sup>r</sup> cells and methotrexate-resistant clones were isolated as per standard procedures. The LT $\beta$ -R-Ig was secreted into the medium and an ELISA assay was used to select for cell lines producing the highest level of the receptor fusion protein. A high-producing cell line was grown to large numbers and the conditioned medium collected. The pure LT $\beta$  receptor fusion protein was isolated by Protein A Sepharose Fast Flow affinity chromatography (Pharmacia).

#### **EXAMPLE 2**

##### **Preparation of Soluble Murine LT $\beta$ Receptors as Immunoglobulin Fusion Proteins**

A complete cDNA clone of the murine LT $\beta$ -R was prepared by ligating a 5' NotI/ApaLI and 3' ApaLI/NotI fragments from two partial cDNA isolates into the NotI site of pCDNA3 (InVitrogen, San Diego, CA). The sequence of this cDNA clone is accessible as GenBank entry U29173. No coding sequence differences were noted when compared with another sequence entry for murine LT $\beta$ -R found in GenBank entry L38423.

A soluble murine LT $\beta$ -R/ human IgG1 fusion protein was prepared by PCR amplification of the full length mLT $\beta$ -R cDNA clone as a template and the primers 5'AACTGCAGCGGCCGCCATGCGCCTGCC 3' and 5'GACTTGTGACCATGGCTCCTGGCTCTGGGG 3'. The amplified product was purified and cut with NotI and SalI and ligated with a SalI/NotI human IgG1 Fc fragment into NotI-linearized and phosphatase-treated SAB132 to form JLB 122. For stable expression, the NotI cassette containing the murine LT $\beta$ -R-Ig fragment was transferred into the NotI site of pMDR901 forming PSH001 and the vector was transfected into CHO cells as described (Browning et al., J. Immunol., 154, pp. 33-46

(1995)). Cell clones secreting murine LT $\beta$ -R-Ig were identified by ELISA analysis. The purified receptor fusion protein was isolated from CHO cell supernatants by Protein A Sepharose Fast Flow chromatography (Pharmacia) and is utilized  
5 in the examples which follow.

### **EXAMPLE 3**

#### **Immunohistochemical analysis of spleen following multiple injections of mice with LT $\beta$ -R-Ig**

4-5 week old mice received six injections, one per week, of LT $\beta$ -R-Ig or LFA-3-Ig (100  $\mu$ g ip), and were immunized with SRBC on the day of the sixth fusion protein injection. Mice then received an additional injection of LT $\beta$ -R-Ig or LFA-3-Ig on  
15 day 4 after challenge with SRBC. The animals were sacrificed on day 10 after challenge with SRBC and organs were harvested for analysis of structure. The left column of Figure 2 represents spleen sections from animals treated with LFA-3-Ig (A, C, E, G, I) and the right column from animals treated with  
20 LT $\beta$ -R-Ig (B, D, F, H, J). Acetone-fixed frozen spleen sections were double stained with biotinylated anti-mouse B220 labeled and anti-mouse CD4 antibodies (A and B), followed by a corresponding second staining with alkaline phosphatase-labeled streptavidin (purple blue, dark staining) and horseradish peroxidase-labeled mouse anti-rat Ig with (light brown staining), respectively. Another set of frozen sections  
25 were stained with ER-TR-9 (to detect MZM, C and D), MOMA-1 (to detect metallophilic macrophages, E and F), MECA-367 (specific for MAdCAM-1, G and H), and ER-TR-7 (to stain reticular fibroblasts, I and J) antibodies, followed by a second staining with a horseradish peroxidase-labeled mouse anti-rat Ig (brown staining). These pictures are representative staining of sections from a minimum of six animals.  
30 Magnification 10X.

**EXAMPLE 4****Effect of LT $\beta$ -R-Ig and anti-CD40 ligand on GC formation and  
5 FDC staining.**

Animals were treated as described in example 3 with LT $\beta$ -R-Ig or LFA-3-Ig. Another group of animals was treated with MR1 (anti-mouse CD40 ligand, 250  $\mu$ g/injection, intraperitoneally) on day -1, day 1 and day 3, received SRBC on day 0 and were 10 killed on day 10. Acetone-fixed spleen sections of animals treated with LFA-3-Ig (Figure 3 left column, A and D), or LT $\beta$ -R-Ig (middle column, B and E), or MR1 (right column, C and F) were stained with biotin-labeled peanut agglutinin (PNA, upper row, A, B and C) or with FDC-M1 (lower row, D, E and F), 15 followed by a second staining with a horseradish peroxidase-labeled streptavidin and horseradish peroxidase-labeled mouse anti-rat Ig, respectively (brown staining). PNA staining of the marginal zone is indicated by an arrow in A and C. GC formation is indicated by a white star in A. Staining for FDC 20 is indicated by a black arrow in D and F. These pictures are representative staining of sections from at least four animals. Magnification 10X.

**EXAMPLE 5**

25

**Addressin expression in LN of mice treated in utero and continuously post-birth with LT $\beta$ -R-Ig**

These experiments used the progeny of timed pregnant Balb/c mice which were injected iv on days 14 and 17 of gestation 30 with 200  $\mu$ g of receptor-Ig proteins. After birth the progeny were injected ip once per week with 100  $\mu$ g of LT $\beta$ -R-Ig, TNF-R55-Ig, or LFA-3-Ig. Fusion protein levels remained at or above 10  $\mu$ g/ml throughout life as determined by ELISA (data not shown). Figure 4: Panels A, B, G, H staining of lymph

nodes from mice treated with LT $\beta$ -R-Ig. Panels C,D staining of lymph nodes from mice treated with LFA-3-Ig, Panels E,F staining of lymph nodes from mice treated with TNF-R55-Ig. Panels A,C,E,G are mesenteric lymph nodes stained with the antibody MECA367 to detect the mucosal addressin, MAdCAM-1. Panels B,D,F,H are peripheral (brachial) lymph nodes stained with the antibody MECA79 specific for peripheral LN addressins (PNAAds). Panels G,H are lymph nodes from 6 week old mice exposed to LT $\beta$ -R-Ig in utero only. All images are 50X magnification.

#### **EXAMPLE 6**

15 **Lymphocyte positioning and expression of macrophage markers in LN of mice treated in utero and continuously post-birth with LT $\beta$ -R-Ig.** Mice were treated in utero and continuously postbirth as described for example 5 with LT $\beta$ -R-Ig, TNF-R55-Ig, or LFA-3-Ig. LN sections were then stained with antibodies specific for markers expressed by macrophages or with mAbs specific for the B cell marker B220 and the T cell marker CD4. 20 Image analysis was used in order to identify areas of overlap of T and B cell zones. Figure 5: Panels A,D,G are B220/CD4 staining of LN from LT $\beta$ -R-Ig, LFA-3-Ig and TNF-R55-Ig treated mice respectively. Fluorescent images were analyzed using 25 image analysis software. Panels B,E,H are staining for sialoadhesin and panels C,F,I are staining for MOMA-1.

#### **EXAMPLE 7**

30 **Effect of LT $\beta$ -R-Ig treatment on the antibody response to SRBC.** Balb/c mice were injected with either LT $\beta$ -R-Ig, human Ig or PBS as follows: Figure 6A: mice received six injections as described for figure 2, example 3. Animals were bled day 7 (black bars) and day 14 (striped bars) after SRBC

immunization. 6B: Animals received the fusion proteins on day -7 and day 0. SRBC were given on day 0 and the animals were bled on day 7 (black bars), day 14 (striped bars) and day 30 (white bars). 6C: Animals received the fusion proteins once 5 on day 0, at the same time as the SRBC immunization. The blood was collected on day 7 (black bars), day 14 (striped bars) and day 34 (grey bars).

The titer of SRBC-specific IgM and IgG was determined by analyzing the sera in hemagglutination assays. The titer is 10 defined as the reciprocal of the last serum dilution for which hemagglutination is detected and is represented on a log base 2 scale (1=dilution 1/15 of the sera). Results are represented as the mean of 4 different animals per group with standard deviations.

15

What is claimed is:

1. A method for altering the humoral immune response in an animal comprising the step of
  - a) administering a pharmaceutical composition which comprises a therapeutically effective amount of a LT- $\beta$ -R blocking agent.
2. The method according to claim 1, wherein the LT- $\beta$ -R blocking agent is selected from the group consisting of: soluble lymphotoxin- $\beta$  receptor, an antibody directed against LT- $\beta$  receptor, and an antibody directed against surface LT ligand.
3. The method according to claim 1, wherein the animal is a mammal.
4. The method according to claim 3, wherein the mammal is a human.
5. The method according to claim 2, wherein the LT- $\beta$ -R blocking agent comprises a soluble lymphotoxin- $\beta$  receptor having a ligand binding domain that can selectively bind to a surface LT ligand.
6. The method according to claim 5, wherein the soluble lymphotoxin- $\beta$  receptor comprises a human immunoglobulin Fc domain.
7. The method according to claim 2, wherein the LT- $\beta$ -R blocking agent comprises a monoclonal antibody directed against LT- $\beta$  receptor.

8. The method according to claim 7, wherein the composition is administered in an amount sufficient to coat LT- $\beta$  receptor-positive cells for about 1 to about 14 days.
9. The method according to claim 7, wherein the LT- $\beta$ -R blocking agent comprises anti-human LT- $\beta$ -R mAb BDA8.
10. The method according to claim 2, wherein the LT- $\beta$ -R blocking agent comprises a monoclonal antibody directed against surface LT ligand.
11. The method according to claim 10, wherein the composition is administered in an amount sufficient to coat surface LT ligand-positive cells for 1 to 14 days.
12. The method according to claim 10, wherein the antibody is directed against a subunit of the LT ligand.
13. The method according to claim 12, wherein the LT- $\beta$ -R blocking agent comprises anti-human LT- $\beta$  mAb B9.
14. The method according to claim 10, wherein the LT- $\beta$ -R blocking agent comprises a monoclonal antibody directed against a murine surface LT ligand.
15. The method of claim 1 further comprising a pharmaceutically acceptable carrier or adjuvant.
16. The method according to claim 1, wherein the humoral immune response is inhibited.
17. A pharmaceutical composition comprising a therapeutically effective amount of a LT- $\beta$ -R blocking agent and a pharmaceutically acceptable carrier.

18. The composition according to claim 38, wherein the LT- $\beta$ -R blocking agent is selected from the group consisting of a soluble lymphotoxin- $\beta$  receptor, an antibody directed against LT- $\beta$  receptor, and an antibody directed against surface LT ligand.
19. A method for inhibiting LT- $\beta$ -R signaling without inhibiting TNF-R signaling comprising the step of administering to a subject an effective amount of a LT- $\beta$ -R blocking agent.
20. The method according to claim 19, wherein the LT- $\beta$ -R blocking agent is selected from the group consisting of a soluble lymphotoxin- $\beta$  receptor, an antibody directed against LT- $\beta$  receptor, and an antibody directed against surface LT ligand.
21. The method according to claim 19, wherein the subject comprises one or more cells from a mammal.
22. The method according to claim 21, wherein the mammal is a human.
23. The method according to claim 19, wherein the LT- $\beta$ -R blocking agent comprises a soluble lymphotoxin- $\beta$  receptor having a ligand binding domain that can selectively bind to a surface LT ligand.
24. The method according to claim 23, wherein the soluble lymphotoxin- $\beta$  receptor further comprises a human immunoglobulin Fc domain.
25. The method according to claim 19, wherein the LT- $\beta$ -R blocking agent comprises a monoclonal antibody directed against LT- $\beta$  receptor.

26. The method according to claim 22, wherein the LT- $\beta$ -R blocking agent comprises anti-human LT- $\beta$ -R mAb BDA8.

27. The method according to claim 19, wherein the LT- $\beta$ -R blocking agent comprises a monoclonal antibody directed against surface LT ligand.

28. A method for altering the association of immune complexes and B cell follicles in a patient comprising administering an amount of an LT- $\beta$ -R blocking agent to said patient.

29. The method of claim 28 wherein said patient is infected with human immunodeficiency virus.

30. The method of claim 28 wherein said blocking agent is selected from the group consisting of soluble LT- $\beta$ -R, an antibody directed against LT- $\beta$ -R, and an antibody directed against surface LT ligand.

31. The method of claim 30 wherein said soluble LT- $\beta$ -R has a ligand binding domain that can selectively bind to a surface LT ligand.

32. The method of claim 31 wherein said soluble receptor comprises a human immunoglobulin Fc domain.

33. The method of claim 28 wherein the LT- $\beta$ -R comprises a monoclonal antibody directed against LT- $\beta$ -R.

34. The method of claim 33 wherein said antibody is an anti-human LT- $\beta$ -R mAb BDA8.

35. The method of claim 28 further comprising a pharmaceutically acceptable carrier or adjuvant.

36. A method of treating, preventing, or eliminating human immunodeficiency virus in a mammal comprising the step of administering a pharmaceutical composition comprising a therapeutically effective amount of a LT- $\beta$ -R blocking agent, and a pharmaceutically effective carrier.

37. The method of claim 36 wherein the LT- $\beta$ -R blocking agent is selected from the group consisting of soluble lymphotoxin  $\beta$ -R, and antibody directed against LT- $\beta$ -R, and an antibody directed against surface LT ligand.

38. The method of claim 37 wherein the blocking agent comprises a soluble lymphotoxin - $\beta$ -R comprising a ligand binding domain that can selectively bind to a surface LT ligand.

39. The method of claim 38 wherein the soluble receptor comprises a human immunoglobulin Fc domain.

40. The method of claim 36 wherein the LT- $\beta$ -R blocking agent comprises a monoclonal antibody directed against LT- $\beta$ -R.

41. The method of claim 40 wherein the blocking agent comprises anti-human LT- $\beta$ -R mAb BDA8.

42. The method of claim 36 wherein the blocking agent comprises a monoclonal antibody directed against surface LT ligand.

43. The method of claim 36 further comprising the co-administration of an additional anti-viral agent.

44. The method of claim 28 wherein the B cells are follicular dendritic cells.

45. A pharmaceutical composition for treating graft rejection comprising a therapeutically effective amount of a blocking agent of LT- $\beta$ -R and a therapeutically effective amount of a blocking agent of CD40L.

46. The composition of claim 45 wherein the LT- $\beta$ -R blocking agent is LT- $\beta$ -R/IgG and the blocking agent of CD40L is an anti CD40L compound.

47. A pharmaceutical composition for the treatment of AIDS or HIV, comprising AZT, a protease inhibitor, and a blocking agent of LT- $\beta$ -R.

48. The composition of claim 47 wherein the blocking agent is LT- $\beta$ -R/IgG fusion.

49. The composition of claim 46 wherein the anti-CD40L compound is a monoclonal antibody.

50. The composition of claim 49 wherein the antibody is 5c8.


ABSTRACT

Compositions and methods comprising "lymphotoxin- $\beta$  receptor blocking agents" which block lymphotoxin- $\beta$  receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

**Fig. 1**


1	SQPQAVPPYA SENQTCRDQE KEYYEPQHRI CCSRCPPGTY VSAKCSRIRD	50
51	TVCATCAENS YNEHWNYLTI CQLCRPCDPV MGLEEIAPCT SKRKTQCRCQ	100
101	PGMFCAAVAL ECTHCELLSD CPPGTEAELK DEVGKGNNHC VPCCKAGHFQN	150
151	TSSPSARCQP HTRCENQGLV EAAPGTAQSD TTCKNPLEPL PPEMSGT	197

FIGURE 2



65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80

FIGURE 3




# FIGURE 4

MAdCAM-1 staining


PNAd staining

**A**

LT $\beta$ -RIg



**B**



**C**

LFA3Ig



**D**



**E**

TNFR55Ig




**F**




**G**

LT $\beta$ -RIg, gs only



**H**



# FIGURE 5





FIGURE 6



# Immune complexe trapping on FDC




FIGURE 7

Docket No.  
A013PCT

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

### SOLUBLE LYMPHOTOXIN-BETA RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES

the specification of which

(check one)

- is attached hereto.
- was filed on (1) 25 OCT 96 (2) 24 OCT 97 as United States Application No. or PCT International Application Number (1) US 60/029,060 (2) PCT/US97/19436  
and was amended on 14 JAN 1999

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s) Priority Not Claimed

PCT/ US 97/19436 (Number)	PCT (Country)	24 OCT 97 (Day/Month/Year Filed)	<input type="checkbox"/>
<hr/>	<hr/>	<hr/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

US 60/029,060

(Application Serial No.)

25 OCT 96

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

**COX, Niki 42,446**

**FENTON Gillian M. 36,508**

**FLYNN, Kerry A. 33,693**

**KAPLAN, Warren A. 34,199**


**NOE, Alphonse R. 25,603**


Send Correspondence to:

**14 Cambridge Center, Cambridge MA 02142**

Direct Telephone Calls to: *(name and telephone number)*

**Kerry A. Flynn, Esq. (617) 679-3583**

Full name of sole or first inventor <b>BROWNING, Jeffrey</b>	Sole or first inventor's signature 	Date <b>4/12/99</b>
Residence <b>32 Milton Road, Brookline, MA 02146</b>		
Citizenship <b>US</b>		
Post Office Address		

Full name of second inventor, if any <b>HOCHMAN, Paula Susan</b>	Second inventor's signature 	Date <b>4/12/99</b>
Residence <b>14 White Avenue, Newton, MA 02159</b>		
Citizenship <b>US</b>		
Post Office Address		


Full name of third inventor, if any <b>RENNERT, Paul D.</b>	
Third inventor's signature 	Date 4/12/99
Residence <b>2 Skyview Terrace, Holliston, MA 01746</b>	<b>278 Ridge St, Millis, MA 02054</b>
Citizenship	
Post Office Address	

Full name of fourth inventor, if any <b>MACKAY, Fabienne</b>	
Fourth inventor's signature 	Date 4/12/99
Residence <b>126 Church Street, Watertown, MA 02172</b>	<b>36 NEWBROOK CIRCLE NEWTON C. HILL MA 02467</b>
Citizenship	
Post Office Address	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

United States Patent & Trademark Office  
Office of Initial Patent Examination - Scanning Division



Application deficiencies were found during scanning:

- Page(s) 8 of 8 of Drawing        were not present  
for scanning. (Document title)
- Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)
- Scanned copy is best available.